

# World Journal of *Gastrointestinal Oncology*

*World J Gastrointest Oncol* 2013 May 15; 5(5): 88-101



## Editorial Board

2011-2015

The *World Journal of Gastrointestinal Oncology* Editorial Board consists of 428 members, representing a team of worldwide experts in gastrointestinal oncology. They are from 40 countries, including Argentina (2), Australia (10), Belgium (5), Brazil (2), Canada (4), Chile (2), China (56), Czech Republic (1), Denmark (1), Finland (3), France (7), Germany (24), Greece (13), Hungary (2), India (9), Iran (2), Ireland (2), Israel (4), Italy (41), Japan (47), Kuwait (2), Mexico (1), Netherlands (7), New Zealand (2), Norway (1), Poland (3), Portugal (5), Romania (1), Saudi Arabia (1), Serbia (2), Singapore (4), South Korea (27), Spain (10), Sweden (5), Switzerland (2), Syria (1), Thailand (1), Turkey (6), United Kingdom (15), and United States (95).

### EDITORS-IN-CHIEF

Wasaburo Koizumi, *Kanagawa*  
Hsin-Chen Lee, *Taipei*  
Dimitrios H Roukos, *Ioannina*

### STRATEGY ASSOCIATE

#### EDITORS-IN-CHIEF

Jian-Yuan Chai, *Long Beach*  
Antonio Macrì, *Messina*  
Markus Kurt Menges, *Schwaebisch Hall*

### GUEST EDITORIAL BOARD MEMBERS

Da-Tian Bau, *Taichung*  
Jui-I Chao, *Hsinchu*  
Chiao-Yun Chen, *Kaohsiung*  
Joanne Jeou-Yuan Chen, *Taipei*  
Shih-Hwa Chiou, *Taipei*  
Tzeon-Jye Chiou, *Taipei*  
Jing-Gung Chung, *Taichung*  
Yih-Gang Goan, *Kaohsiung*  
Li-Sung Hsu, *Taichung*  
Tsann-Long Hwang, *Taipei*  
Long-Bin Jeng, *Taichung*  
Kwang-Huei Lin, *Taoyuan*  
Joseph T Tseng, *Tainan*  
Jaw Yuan Wang, *Kaohsiung*  
Tzu-Chen Yen, *Taoyuan*

### MEMBERS OF THE EDITORIAL BOARD



#### Argentina

María Eugenia Pasqualini, *Córdoba*  
Lydia Inés Puricelli, *Buenos Aires*



#### Australia

Ned Abraham, *NSW*

Stephen John Clarke, *NSW*  
Michael Gnant, *Vienna*  
Michael McGuckin, *South Brisbane*  
Muhammed Ashraf Memon, *Queensland*  
Liang Qiao, *NSW*  
Rodney John Scott, *NSW*  
Joanne Patricia Young, *Herston Q*  
Xue-Qin Yu, *NSW*  
Xu Dong Zhang, *NSW*



#### Belgium

Wim Peter Ceelen, *Ghent*  
Van Cutsem Eric, *Leuven*  
Suriano Gianpaolo, *Brussels*  
Xavier Sagaert, *Leuven*  
Jan B Vermorken, *Edegem*



#### Brazil

Raul Angelo Balbinotti, *Caxias do Sul*  
Sonia Maria Oliani, *Colombo*



#### Canada

Alan Graham Casson, *Saskatoon*  
Hans Tse-Kan Chung, *Toronto*  
Rami Kotb, *Sherbrooke*  
Sai Yi Pan, *Ottawa*



#### Chile

Alejandro Hernan Corvalan, *Santiago*  
Juan Carlos Roa, *Temuco*



#### China

Dong Chang, *Beijing*  
George G Chen, *Hong Kong*  
Yong-Chang Chen, *Zhenjiang*  
Chi-Hin Cho, *Hong Kong*  
Ming-Xu Da, *Lanzhou*  
Xiang-Wu Ding, *Xiangfan*  
Yan-Qing Ding, *Guangzhou*  
Bi Feng, *Chengdu*  
Jin Gu, *Beijing*  
Qin-Long Gu, *Shanghai*  
Hai-Tao Guan, *Xi'an*  
Chun-Yi Hao, *Beijing*  
Yu-Tong He, *Shijiazhuang*  
Jian-Kun Hu, *Chengdu*  
Huang-Xian Ju, *Nanjing*  
Wai-Lun Law, *Hong Kong*  
Ming-Yu Li, *Lanzhou*  
Shao Li, *Beijing*  
Ka-Ho Lok, *Hong Kong*  
Maria Li Lung, *Hong Kong*  
Simon Ng, *Hong Kong*  
Wei-Hao Sun, *Nanjing*  
Qian Tao, *Hong Kong*  
Bin Wang, *Nanjing*  
Chun-You Wang, *Wuhan*  
Kai-Juan Wang, *Zhengzhou*  
Wei-Hong Wang, *Beijing*  
Ya-Ping Wang, *Nanjing*  
Ai-Wen Wu, *Beijing*  
Zhao-Lin Xia, *Shanghai*  
Xue-Yuan Xiao, *Beijing*  
Dong Xie, *Shanghai*  
Guo-Qiang Xu, *Hangzhou*  
Yi-Zhuang Xu, *Beijing*  
Winnie Yeo, *Hong Kong*  
Ying-Yan Yu, *Shanghai*

Siu Tsan Yuen, *Hong Kong*  
Wei-Hui Zhang, *Harbin*  
Li Zhou, *Beijing*  
Yong-Ning Zhou, *Lanzhou*



### Czech Republic

Ondrej Slaby, *Brno*



### Denmark

Hans Jørgen Nielsen, *Hvidovre*



### Finland

Riyad Bendardaf, *Turku*  
Pentti Ilmari Sipponen, *Espoo*  
Markku Voutilainen, *Jyväskylä*



### France

Bouvier Anne-Marie, *Cedex*  
Stéphane Benoist, *Boulogne*  
Ouaissi Mehdi, *Marseille*  
Jean-François Rey, *Jean-François Rey*  
Karem Slim, *Clermont-Ferrand*  
David Tougeron, *Poitiers*  
Isabelle Van Seuning, *Lille*



### Germany

Hajri Amor, *Freiburg*  
Han-Xiang An, *Marburg*  
Karl-Friedrich Becker, *München*  
Stefan Boeck, *Munich*  
Dietrich Doll, *Marburg*  
Joachim Drevs, *Freiburg*  
Volker Ellenrieder, *Marburg*  
Ines Gütgemann, *Bonn*  
Jakob Robert Izbicki, *Hamburg*  
Gisela Keller, *München*  
Jörg H Kleeff, *Munich*  
Axel Kleespies, *Munich*  
Hans-Joachim Meyer, *Solingen*  
Lars Mueller, *Kiel*  
Martina Müller-Schilling, *Heidelberg*  
Joachim Pfannschmidt, *Heidelberg*  
Marc André Reymond, *Bielefeld*  
Robert Rosenberg, *München*  
Ralph Schneider, *Marburg*  
Helmut K Seitz, *Heidelberg*  
Nikolas Hendrik Stoecklein, *Düsseldorf*  
Oliver Stoeltzing, *Mainz*  
Ludwig G Strauss, *Heidelberg*



### Greece

Ekaterini Chatzaki, *Alexandroupolis*  
Eelco de Bree, *Heraklion*  
Maria Gazouli, *Athens*  
Vassilis Georgoulas, *Heraklion*  
John Griniatsos, *Athens*  
Ioannis D Kanellos, *Thessaloniki*  
Vaios Karanikas, *Larissa*  
Georgios Koukourakis, *Athens*

Michael I Koukourakis, *Alexandroupolis*  
Gregory Kouraklis, *Athens*  
Kostas Syrigos, *Athens*  
Ioannis A Voutsadakis, *Larissa*



### Hungary

László Herszényi, *Budapest*  
Zsuzsa Schaff, *Budapest*



### India

Uday Chand Ghoshal, *Lucknow*  
Ruchika Gupta, *New Delhi*  
Kalpesh Jani, *Vadodara*  
Ashwani Koul, *Chandigarh*  
Balraj Mittal, *Lucknow*  
Rama Devi Mittal, *Lucknow*  
Susanta Roychoudhury, *Kolkata*  
Yogeshwar Shukla, *Lucknow*  
Imtiaz Ahmed Wani, *Kashmir*



### Iran

Reza Malekzadeh, *Tehran*  
Mohamad Amin Pourhoseingholi, *Tehran*



### Ireland

Aileen Maria Houston, *Cork*  
Colm Ó'Moráin, *Dublin*



### Israel

Nadir Arber, *Tel Aviv*  
Eytan Domany, *Rehovot*  
Dan David Hershko, *Haifa*  
Yaron Niv, *Patch Tikva*



### Italy

Massimo Aglietta, *Turin*  
Domenico Alvaro, *Rome*  
Azzariti Amalia, *Bari*  
Marco Braga, *Milan*  
Federico Cappuzzo, *Rozzano*  
Lorenzo Capussotti, *Torino*  
Fabio Carboni, *Rome*  
Vincenzo Cardinale, *Rome*  
Luigi Cavanna, *Piacenza*  
Massimo Colombo, *Milan*  
Valli De Re, *Pordenone*  
Ferdinando De Vita, *Naples*  
Riccardo Dolcetti, *Aviano*  
Pier Francesco Ferrucci, *Milano*  
Francesco Fiorica, *Ferrara*  
Gennaro Galizia, *Naples*  
Silvano Gallus, *Milano*  
Milena Gusella, *Trecenta*  
Carlo La Vecchia, *Milano*  
Roberto Francesco Labianca, *Bergamo*  
Massimo Libra, *Catania*  
Roberto Manfredi, *Bologna*  
Gabriele Masselli, *Viale del Policlinico*  
Simone Mocellin, *Padova*

Gianni Mura, *Arezzo*  
Gerardo Nardone, *Napoli*  
Gabiella Nesi, *Florence*  
Francesco Perri, *San Giovanni Rotondo*  
Francesco Recchia, *Avezzano*  
Vittorio Ricci, *Pavia*  
Fabrizio Romano, *Monza*  
Antonio Russo, *Palermo*  
Daniele Santini, *Rome*  
Claudio Sorio, *Verona*  
Cosimo Sperti, *Padova*  
Gianni Testino, *Genova*  
Giuseppe Tonini, *Rome*  
Bruno Vincenzi, *Rome*  
Zoli Wainer, *Forlì*  
Angelo Zullo, *Rome*



### Japan

Suminori Akiba, *Kagoshima*  
Keishiro Aoyagi, *Kurume*  
Narikazu Boku, *Shizuoka*  
Yataro Daigo, *Tokyo*  
Itaru Endo, *Yokohama*  
Mitsuhiro Fujishiro, *Tokyo*  
Osamu Handa, *Kyoto*  
Kenji Hibi, *Yokohama*  
Asahi Hishida, *Nagoya*  
Eiso Hiyama, *Hiroshima*  
Atsushi Imagawa, *Okayama*  
Johji Inazawa, *Tokyo*  
Terumi Kamisawa, *Tokyo*  
Tatsuo Kanda, *Niigata*  
Masaru Katoh, *Tokyo*  
Takayoshi Kiba, *Hyogo*  
Hajime Kubo, *Kyoto*  
Hiroki Kuniyasu, *Kashihara*  
Yukinori Kurokawa, *Osaka*  
Chihaya Maesawa, *Morioka*  
Yoshinori Marunaka, *Kyoto*  
Osam Mazda, *Kyoto*  
Shinichi Miyagawa, *Matsumoto*  
Eiji Miyoshi, *Suita*  
Toshiyuki Nakayama, *Nagasaki*  
Masahiko Nishiyama, *Saitama*  
Koji Oba, *Kyoto*  
Masayuki Ohtsuka, *Chiba*  
Masao Seto, *Aichi*  
Tomoyuki Shibata, *Aichi*  
Mitsugi Shimoda, *Tochigi*  
Haruhiko Sugimura, *Hamamatsu*  
Tomomitsu Tahara, *Aichi*  
Shinji Takai, *Osaka*  
Satoru Takayama, *Nagoya*  
Akio Tomoda, *Tokyo*  
Akihiko Tsuchida, *Tokyo*  
Yasuo Tsuchiya, *Niigata*  
Takuya Watanabe, *Niigata*  
Toshiaki Watanabe, *Tokyo*  
Yo-ichi Yamashita, *Hiroshima*  
Hiroki Yamaue, *Wakayama*  
Hiroshi Yasuda, *Kanagawa*  
Hiroshi Yokomizo, *Kumamoto*  
Yutaka Yonemura, *Osaka*  
Reigetsu Yoshikawa, *Hyogo*



### Kuwait

Fahd Al-Mulla, *Safat*

Salem Alshemmari, *Safat*



**Mexico**

Oscar G Arrieta Rodriguez, *Mexico City*



**Netherlands**

Jan Paul De Boer, *Amsterdam*  
Bloemena Elisabeth, *Bloemena Elisabeth*  
Peter JK Kuppen, *Leiden*  
Gerrit Albert Meijer, *Amsterdam*  
Anyan N Milne, *Utrecht*  
Godefridus J Peters, *Amsterdam*  
Cornelis FM Sier, *Leiden*



**New Zealand**

Lynnette Robin Ferguson, *Auckland*  
Jonathan Barnes Koea, *Auckland*



**Norway**

Kjetil Søreide, *Stavanger*



**Poland**

Andrzej Szkaradkiewicz, *Poznan*  
Michal Tenderenda, *Polskiego*  
Jerzy Wydmański, *Gliwice*



**Portugal**

Maria de Fátima Moutinho Gärtner, *Porto*  
Celso Albuquerque Reis, *Porto*  
Lucio Lara Santos, *Porto*  
Maria Raquel Campos Seruca, *Porto*  
Manuel António Rodrigues Teixeira, *Porto*



**Romania**

Marius Raica, *Timisoara*



**Saudi Arabia**

Ragab Hani Donkol, *Abha*



**Serbia**

Milos M Bjelovic, *Belgrade*  
Goran Zoran Stanojevic, *Nis*



**Singapore**

Peh Yean Cheah, *Singapore*  
Si-Shen Feng, *Singapore*  
Zhi-Wei Huang, *Singapore*  
Qi Zeng, *Singapore*



**South Korea**

Seungmin Bang, *Seoul*  
Daeho Cho, *Seoul*  
Byung Ihn Choi, *Seoul*  
Hyun Cheol Chung, *Seoul*  
Sang-Uk Han, *Suwon*  
Jun-Hyeog Jang, *Incheon*  
Seong Woo Jeon, *Daegu*  
Dae Hwan Kang, *Mulgeum-Gigu*  
Gyeong Hoon Kang, *Seoul*  
Dong Yi Kim, *Gwangju*  
Jae J Kim, *Seoul*  
Jin Cheon Kim, *Seoul*  
Jong Gwang Kim, *Daegu*  
Min Chan Kim, *Busan*  
Samyong Kim, *Daejeon*  
Inchul Lee, *Seoul*  
Jung Weon Lee, *Seoul*  
Kyu Taek Lee, *Seoul*  
Kyung Hee Lee, *Daegu*  
Na Gyong Lee, *Seoul*  
Suk Kyeong Lee, *Seoul*  
Jong-Baeck Lim, *Seoul*  
Young Joo Min, *Ulsan*  
Sung-Soo Park, *Seoul*  
Young Kee Shin, *Seoul*  
Hee Jung Son, *Seoul*  
Si Young Song, *Seoul*



**Spain**

Manuel Benito, *Madrid*  
Ignacio Casal, *Madrid*  
Antoni Castells, *Barcelona*  
Jose JG Marin, *Salamanca*  
Joan Maurel, *Barcelona*  
Emma Folch Puy, *Barcelona*  
Jose Manuel Ramia, *Guadalajara*  
Margarita Sanchez-Beato, *Madrid*  
Laura Valle, *Barcelona*  
Jesus Vioque, *San Juan*



**Sweden**

Nils Albiin, *Stockholm*  
Samuel Lundin, *Göteborg*  
Haile Mahteme, *Uppsala*  
Richard Palmqvist, *Umea*  
Ning Xu, *Lund*



**Switzerland**

Paul M Schneider, *Zurich*  
Luigi Tornillo, *Basel*



**Syria**

Zuhir Alshehabi, *Lattakia*



**Thailand**

Sopit Wongkham, *Khon Kaen*



**Turkey**

Uğur Coşkun, *Ankara*  
Sukru Mehmet Erturk, *Istanbul*  
Vedat Goral, *Diyarbakir*  
Yavuz Selim Sari, *Istanbul*  
Mesut Tez, *Ankara*  
Murat H Yener, *Istanbul*



**United Kingdom**

Shrikant Anant, *Oklahoma City*  
Runjan Chetty, *Scotland*  
Chris Deans, *Edinburgh*  
Dipok Kumar Dhar, *London*  
Thomas Ronald Jeffry Evans, *Glasgow*  
Giuseppe Garcea, *Leicester*  
Oleg Gerasimenko, *Liverpool*  
Neena Kalia, *Birmingham*  
Anthony Maraveyas, *East Yorkshire*  
Andrew Maw, *North Wales*  
Kymberley Thorne, *Swansea*  
Chris Tselepis, *Birmingham*  
Nicholas Francis Scot Watson, *Nottingham*  
Ling-Sen Wong, *Coventry*  
Lu-Gang Yu, *Liverpool*



**United States**

Mohammad Reza Abbaszadegan, *Phoenix*  
Gianfranco Alpini, *Temple*  
Seung Joon Baek, *Knoxville*  
Jamie S Barkin, *Miami Beach*  
Carol Bernstein, *Arizona*  
Paolo Boffetta, *New York*  
Kimberly Maureen Brown, *Kansas City*  
De-Liang Cao, *Springfield*  
Weibiao Cao, *Providence*  
Chris N Conteas, *Los Angeles*  
Pelayo Correa, *Nashville*  
Joseph John Cullen, *JCP*  
James Campbell Cusack, *Boston*  
Ananya Das, *Scottsdale*  
Juan Dominguez-Bendala, *Miami*  
Wafik S El-Deiry, *Philadelphia*  
Laura Elnitski, *Rockville*  
Guy Douglas Eslick, *Boston*  
Thomas Joseph Fahey III, *New York*  
James W Freeman, *San Antonio*  
Bruce Joseph Giantonio, *Philadelphia*  
Ajay Goel, *Dallas*  
Karen Gould, *Omaha*  
Nagana Gowda A Gowda, *West Lafayette*  
Stephen Randolph Grobmyer, *Florida*  
Young S Hahn, *Charlottesville*  
John W Harmon, *Maryland*  
Paul J Higgins, *New York*  
Steven Norbit Hochwald, *Gainesville*  
Jason L Hornick, *Boston*  
Qin Huang, *Duarte*  
Su-Yun Huang, *Houston*  
Jamal A Ibdah, *Columbia*  
Yihong Jiang-Cao Kaufmann, *Little Rock*  
Temitope Olubunmilayo Keku, *Chapel Hill*  
Saeed Khan, *Silver Spring*  
Vijay Pranjivan Khatri, *Sacramento*

Peter Sean Kozuch, *New York*  
Sunil Krishnan, *Houston*  
Robert R Langley, *Houston*  
Feng-Zhi Li, *New York*  
Otto Schiueh-Tzang Lin, *Seattle*  
Ke-Bin Liu, *Augusta*  
Rui-Hai Liu, *Ithaca*  
Xiang-Dong Liu, *Wilmington*  
Deryk Thomas Loo, *South San Francisco*  
Andrew M Lowy, *La Jolla*  
Bo Lu, *Nashville*  
David M Lubman, *Ann Arbor*  
James David Luketich, *Pittsburgh*  
Ju-Hua Luo, *Morgantown*  
Henry T Lynch, *Omaha*  
Shelli R Mcalpine, *San Diego*  
Ellen Darcy McPhail, *Rochester*  
Anil Mishra, *Cincinnati*  
Priyabrata Mukherjee, *Rochester*

Steffan Todd Nawrocki, *San Antonio*  
Kevin Tri Nguyen, *Pittsburgh*  
Shuji Ogino, *Boston*  
Macaulay Onuigbo, *Eau Claire*  
Jong Park, *Tampa*  
Philip Agop Philip, *Detriot*  
Blase N Polite, *Chicago*  
James Andrew Radosevich, *Chicago*  
Jasti S Rao, *Peoria*  
Srinevas Kadumpalli Reddy, *Durham*  
Raffaniello Robert, *New York*  
Stephen H Safe, *College Station*  
Muhammad Wasif Saif, *New Haven*  
Prateek Sharma, *Kansas City*  
Eric Tatsuo Shinohara, *Philadelphia*  
Liviu Andrei Sicinschi, *Nashville*  
William Small Jr, *Chicago*  
Sanjay K Srivastava, *Amarillo*  
Gloria H Su, *New York*

Sujha Subramanian, *Waltham*  
Mitsushige Sugimoto, *Texas*  
David W Townsend, *Knoxville*  
Asad Umar, *Rockville*  
Ji-Ping Wang, *Buffalo*  
Zheng-He Wang, *Cleveland*  
Michael J Wargovich, *Charleston*  
Neal W Wilkinson, *Iowa City*  
Siu-Fun Wong, *Pomona*  
Shen-Hong Wu, *New York*  
Jing-Wu Xie, *Indianapolis*  
Ke-Ping Xie, *Houston*  
Hao-Dong Xu, *Rochester*  
Xiao-Chun Xu, *Houston*  
Gary Y Yang, *New York*  
Wan-Cai Yang, *Chicago*  
Zeng-Quan Yang, *Detroit*  
Zuo-Feng Zhang, *South Los Angeles*  
Andrew X Zhu, *Boston*



# World Journal of Gastrointestinal Oncology

## Contents

Monthly Volume 5 Number 5 May 15, 2013

**EDITORIAL** 88 Targeted treatments for metastatic esophageal squamous cell cancer  
*Digkila A, Voutsadakis IA*

**MINIREVIEWS** 97 RAS signaling pathways, mutations and their role in colorectal cancer  
*Zenonos K, Kyprianou K*

## Contents

*World Journal of Gastrointestinal Oncology*  
Volume 5 Number 5 May 15, 2013

**APPENDIX** I-V Instructions to authors

**ABOUT COVER** *World Journal of Gastrointestinal Oncology* Editorial Board, Yu-Tong He, Vice-director, Department of cancer epidemiology, Hebei Cancer Institute/Hospital, 12 Jiankang Road, Shijiazhuang 050011, China

**AIM AND SCOPE** *World Journal of Gastrointestinal Oncology (World J Gastrointest Oncol, WJGO, online ISSN 1948-5204, DOI: 10.4251)* is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

*WJGO* covers topics concerning carcinogenesis, tumorigenesis, metastasis, diagnosis, prevention, prognosis, clinical manifestations, nutritional support, molecular mechanisms, and therapy of benign and malignant tumors of the digestive tract. The current columns of *WJGO* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography. Priority publication will be given to articles concerning diagnosis and treatment of gastrointestinal oncology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJGO*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

**INDEXING/ ABSTRACTING** *World Journal of Gastrointestinal Oncology* is now indexed in PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

**FLYLEAF** I-V Editorial Board

### EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xin-Xin Che*  
Responsible Electronic Editor: *Jin-Li Yan*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Sui-Xin Gou*

**NAME OF JOURNAL**  
*World Journal of Gastrointestinal Oncology*

**ISSN**  
ISSN 1948-5204 (online)

**LAUNCH DATE**  
October 15, 2009

**FREQUENCY**  
Monthly

**EDITORS-IN-CHIEF**  
**Wasaburo Koizumi, MD, PhD, Professor, Chairman**, Department of Gastroenterology, Gastrointestinal Oncology, School of Medicine, Kitasato University, 2-1-1 Asamizodai Minamiku Sagamihara Kanagawa 252-0380, Japan

**Hsin-Chen Lee, PhD, Professor**, Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan

**Dimitrios H Roukos, MD, PhD, Professor**, Person-

alized Cancer Genomic Medicine, Human Cancer Biobank Center, Ioannina University, Metabatiko Ktirio Panepistimiou Ioanninon, Office 229, Ioannina, TK 45110, Greece

**EDITORIAL OFFICE**  
Jin-Lei Wang, Director  
Xiu-Xia Song, Vice Director  
*World Journal of Gastrointestinal Oncology*  
Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China  
Telephone: +86-10-85381891  
Fax: +86-10-85381893  
E-mail: wjgo@wjgnet.com  
http://www.wjgnet.com

**PUBLISHER**  
Baishideng Publishing Group Co., Limited  
Flat C, 23/F, Lucky Plaza, 315-321 Lockhart Road, Wanchai, Hong Kong, China  
Fax: +852-6557188  
Telephone: +852-31779906  
E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

**PUBLICATION DATE**  
May 15, 2013

**COPYRIGHT**  
© 2013 Baishideng. Articles published by this Open Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

**INSTRUCTIONS TO AUTHORS**  
Full instructions are available online at [http://www.wjgnet.com/2222-0682/g\\_info\\_20100722180909.htm](http://www.wjgnet.com/2222-0682/g_info_20100722180909.htm).

**ONLINE SUBMISSION**  
<http://www.wjgnet.com/esps/>

## Targeted treatments for metastatic esophageal squamous cell cancer

Antonia Digklla, Ioannis A Voutsadakis

Antonia Digklla, Ioannis A Voutsadakis, Centre Pluridisciplinaire d'Oncologie, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland

Author contributions: Digklla A performed literature search and wrote part of the manuscript; Voutsadakis IA conceived the paper, wrote parts and revised the manuscript.

Correspondence to: Ioannis A Voutsadakis, MD, PhD, Centre Pluridisciplinaire d'Oncologie, Centre Hospitalier Universitaire Vaudois, Bugnon 46, 1011 Lausanne, Switzerland. [ivoutsadakis@yahoo.com](mailto:ivoutsadakis@yahoo.com)

Telephone: +41-21-3145122 Fax: +41-21-2140188

Received: November 12, 2012 Revised: April 18, 2013

Accepted: May 13, 2013

Published online: May 15, 2013

tor; Vascular endothelial growth factor receptor; Mammalian target of rapamycin

**Core tip:** This paper discusses some of these targeted agents in more advanced development in metastatic esophageal squamous cell carcinomas, as well as some promising drugs with pre-clinical or initial clinical data in the disease.

Digklla A, Voutsadakis IA. Targeted treatments for metastatic esophageal squamous cell cancer. *World J Gastrointest Oncol* 2013; 5(5): 88-96 Available from: URL: <http://www.wjgnet.com/1948-5204/full/v5/i5/88.htm> DOI: <http://dx.doi.org/10.4251/wjgo.v5.i5.88>

### Abstract

Squamous cell carcinoma, one of the two major subtypes of esophageal carcinomas, constitutes the great majority of tumors in the upper and middle third of the organ. Declining in incidence in western countries, it continues to be a significant public health problem in the far east. Targeted treatments are novel therapies introduced in the clinical therapeutic armamentarium of oncology in the last 10-15 years. They represent a rational way of treating various cancers based on their molecular lesions. Although no such agent has been approved so far for the treatment of esophageal squamous cell carcinomas (ESCC), several are in clinical trials and several others have displayed pre-clinical activity that would justify the efforts and risks of pursuing their clinical development in this disease. This paper discusses some of these targeted agents in more advanced development in metastatic ESCC, as well as some promising drugs with pre-clinical or initial clinical data in the disease.

© 2013 Baishideng. All rights reserved.

**Key words:** Esophageal carcinoma; Squamous; Targeted therapies; Clinical trials; Epidermal growth factor recep-

### INTRODUCTION

Two major histologic types of esophageal cancers exist and differ in their epidemiology and risk factors. Esophageal adenocarcinomas arise almost exclusively in the lower third of the esophagus and esophagogastric junction, have an increasing incidence in western populations and are associated with Barrett's metaplasia and chronic gastro-esophageal reflux<sup>[1]</sup>. In contrast, esophageal squamous cell carcinomas (ESCC) are mostly situated in the upper two thirds of the organ and are associated with smoking and alcohol<sup>[2]</sup>. Salty foods and nitrosamine compounds in foods have also been implicated<sup>[3]</sup>. Their incidence decreases in western countries but remains a significant public issue in Asian populations<sup>[4]</sup>.

Unfortunately, despite these differences that imply a distinct pathogenesis, the two types are mostly lumped together in clinical trials, a fact that would dilute a possible benefit in only one of the two histologies if the other histology would not benefit from a given treatment. Although this may be true even for chemotherapy as evidenced in the case of pulmonary adenocarcinomas and

squamous cell carcinomas where differences in response to various regimens have been revealed<sup>[5]</sup>, it is particularly important for targeted therapies that would work only if the intended target is expressed, functional and involved in the pathogenesis of a carcinoma. A recent change in the trend of trials in the field of esophageal cancers necessitated by the development of targeted therapies adjoins esophageal adenocarcinomas and adenocarcinomas of the gastro-esophageal junction with gastric adenocarcinomas with which they share a common histology and are at times difficult to discern at the margins of the two organs. For the development of trastuzumab therapy, adenocarcinomas of the gastro-esophageal junction have been included in the trials and those of lower esophagus are often treated with the drug if they display an increased expression or amplification of human epidermal growth factor receptor 2 (HER-2)/Neu<sup>[6]</sup>. With these facts in perspective, the current paper will discuss only data concerning targeted therapies in metastatic or locally advanced inoperable ESCC. For studies that have included both esophageal histologies, discussion will be restricted to patients with squamous histology. When there are significant data available specifically for ESCC on expression of a possible tumor target and preclinical anti-tumor activity of a corresponding therapy, they will be mentioned, as they might represent an opportunity for future clinical development.

## ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR THERAPIES

Immunohistochemical (IHC) studies showed epidermal growth factor receptor (EGFR) protein over-expression in 50% of patients with ESCC and gene amplification was evident in 28% of over-expressors (or 14% of the total patients in the series)<sup>[7]</sup>. Over-expression was significantly correlated with the depth of tumor invasion<sup>[7]</sup>. Mutations in exons 19 and 21 of EGFR were not identified in any of the patients examined. Others have found amplification of EGFR in 15% in a series of 55 patients with ESCC<sup>[8]</sup> and rare EGFR mutations in ESCC specimens and a ESCC cell line<sup>[9,10]</sup>. Half of the patients displayed high levels of EGFR protein expression measured by a semi-quantitative IHC-based method. Protein expression correlated with gene amplification in this and in another series of 105 ESCC patients<sup>[11]</sup>. In this last series EGFR amplification or polysomy by fluorescence *in situ* hybridization (FISH) was seen in 31% of patients<sup>[11]</sup>.

Several studies have examined the efficacy of anti-EGFR therapies in ESCC. Two types of agents targeting the EGFR signaling pathway are available: the anti-EGFR monoclonal antibodies cetuximab and panitumumab and the small molecule tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib.

In metastatic ESCC, a randomized phase II study compared cisplatin 100 mg/m<sup>2</sup>, day 1 and 5-fluorouracil (5-FU) 1000 mg/m<sup>2</sup>/d continuous infusion, days 1-5 every

4 wk with or without cetuximab 250 mg/m<sup>2</sup> weekly (after a loading dose of 400 mg/m<sup>2</sup>) in the first line setting<sup>[12]</sup>. A trend towards longer progression-free survival (PFS) (5.9 mo *vs* 3.6 mo) and overall survival (OS) (9.5 mo *vs* 5.5 mo) was noted in the cetuximab arm. Of interest cetuximab did not exacerbate grade 3 or 4 toxicities, except for rash and diarrhea. A randomized three arm phase II study (CALGB 80403/ECOG 1206) took a reverse approach and sought to determine what chemotherapy is best in combination with cetuximab in metastatic esophageal and gastroesophageal junction cancer<sup>[13]</sup>. Patients were randomized to epirubicin, cisplatin, 5-FU (ECF) or 5-FU, folinic acid, oxaliplatin (FOLFOX) or irinotecan/cisplatin. All three arms received concomitant cetuximab. Only a few (about 10%) of patients had ESCC. Results have been presented so far in an abstract form for the adenocarcinoma patients. The two first arms were more effective and the FOLFOX arm less toxic<sup>[13]</sup>. Conclusions regarding the clinical utility of adding cetuximab to first line chemotherapy are awaiting information from ongoing randomized phase III trials.

Regarding the role of cetuximab in the 2<sup>nd</sup> line chemotherapy setting there is a lack of published trials. A phase II study in the 2<sup>nd</sup> line setting adding cetuximab to cisplatin and irinotecan in patients with irinotecan and cisplatin-refractory metastatic esophageal cancer (NCT 00397904) has completed accrual. This study has included both squamous and adenocarcinomas and results are awaited.

The other clinically available anti-EGFR monoclonal antibody, panitumumab is investigated in combination with chemotherapy in a phase III study (NCT01627379) of non-resectable advanced or metastatic ESCC. Patients included have not been treated with chemotherapy previously (except in the neo-adjuvant setting). All patients receive cisplatin and 5-FU and are randomized to receive or not panitumumab.

A third investigational anti-EGFR antibody, nimotuzumab has been studied in patients with ESCC in the first line metastatic setting in combination with paclitaxel and cisplatin<sup>[14]</sup>. Results of 25 patients treated in a phase II study showed a 63.6% partial response (PR) rate and 31.8% stable disease (SD). The same investigators study nimotuzumab in the second line setting in combination with mFOLFIRI chemotherapy (Trial NCT01486992).

Both orally active TKIs gefitinib and erlotinib that are currently available in clinical practice have been tested in metastatic ESCC. These TKIs block the ATP binding site of the EGFR tyrosine kinase molecule. A phase II trial of gefitinib 500 mg daily in the 2<sup>nd</sup> line treatment of metastatic esophageal cancer showed a higher disease control rate (PR *plus* SD) in patients with SCCs compared with adenocarcinomas ( $P = 0.013$ ). Patients with high EGFR expression and lower levels of phosphorylated kinase adams kara taylor (Akt) had higher disease control rates ( $P = 0.002$  and  $0.009$  respectively)<sup>[15]</sup>. Nine patients with SCC were among the 36 patients enrolled in this study and five (55.5%) showed a PR or SD. Five of six patients tested had a strong expression of EGFR (more than 25%

of tumor cells stained strongly) by IHC. Among the five patients with a PR or SD, all four tested had high EGFR expression. Another phase II trial of gefitinib in recurrent or metastatic esophageal or gastroesophageal junction cancer included 58 patients but only 4 among them had squamous histology<sup>[16]</sup>. Authors state that both histologies derived a clinical benefit but obviously the small number of ESCC patients precludes any definitive conclusion from this study.

A phase III study (NCT01243398) randomizing patients with ESCC and adenocarcinoma to gefitinib versus placebo after one or two lines of chemotherapy is currently ongoing.

Recently a phase II study of erlotinib monotherapy in previously treated esophageal cancer was published<sup>[17]</sup>. Similarly to gefitinib, erlotinib shows activity in squamous cancer. Among the 30 patients included in this study, thirteen patients had squamous histology and twelve of them had some degree of EGFR positivity by IHC (defined as more than 10% of tumor cells staining for the receptor tyrosine kinase). Two patients obtained a response which lasted for 5.5 and 7 mo while seven additional patients had stable disease for a median of 5 mo. The median time to disease progression in all squamous histology patients in the study was 3.3 mo. No correlation of EGFR status and degree of expression with erlotinib efficacy could be established possibly due to the small number of patients.

Overall, interesting activity with acceptable toxicity of anti-EGFR agents is seen in these initial studies. More definitive results from larger trials are expected. Well-validated biomarkers will certainly help to define sub-sets of patients that will benefit most.

## ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 THERAPIES

The benefit of treatment with the humanized anti-HER-2 monoclonal antibody trastuzumab in cases of HER-2 protein over-expressing or gene amplified metastatic breast and gastric adenocarcinomas is well established<sup>[16,18]</sup>. About 15%-20% of squamous esophageal cancers show over-expression of HER-2 by IHC and about 1%-20% show gene amplification by FISH<sup>[19,22]</sup>. Few studies correlated HER-2 status with clinical outcomes in ESCC<sup>[20,21]</sup>. These retrospective studies have shown a worse survival in ESCC when HER-2 is over-expressed. Preclinical data show that trastuzumab, targeting the extracellular domain of the HER-2 protein, has anti-proliferative activity directly but also through antibody dependent cellular cytotoxicity in esophageal carcinoma cells<sup>[23-26]</sup>, providing a rational for clinical trials in ESCC with HER-2 over-expression/amplification. Nevertheless no such studies investigating trastuzumab treatment or treatment with the newer anti-HER-2 agents pertuzumab and trastuzumab emtansine in ESCC have been conducted so far. A phase I study of paclitaxel and trastuzumab with interleukin

12 (trying to take advantage of a natural killer cell mediated cytotoxicity) in HER-2 overexpressing carcinomas has included 4 patients with ESCC<sup>[27]</sup>. Two of them had a partial response lasting for 25 and 43 wk.

## DUAL ANTI-EGFR AND ANTI-HER-2 THERAPIES

Given that a percentage of ESCC overexpress both EGFR and HER-2<sup>[25]</sup>, there is a rational for use of drugs that inhibit both receptors. Lapatinib is a small TKI that inhibits both EGFR and HER-2. A phase II study of lapatinib in recurrent or metastatic ESCC has been initiated (NCT00239200) but has been terminated and there are no published data regarding the outcomes. Another oral TKI pan-HER inhibitor, PF-00299804 is studied in a Korean phase II trial in patients with recurrent and metastatic ESCC (trial NCT01608022). The dual EGFR and HER-2 inhibitor afatinib has been investigated in a phase I study in which one of 7 esophageal cancer patients participating had an unconfirmed partial response<sup>[28]</sup>. Phase II development is pursued only in esophago-gastric adenocarcinomas. Based on the accumulated evidence from other malignancies, it can be expected that the efficacy of anti-EGFR/anti-HER-2 agents would be restricted to tumors with high expression or specific mutations of these receptors. Further development of targeted EGFR/HER-2 drugs should be focused to these sub-sets of ESCC. Although this focusing would limit the pool of available patients and make clinical trials more cumbersome and slow to accrue, it will, on the other hand, increase the probability of obtaining positive results.

## ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPIES

Angiogenesis plays a crucial role in carcinogenesis and progression of malignancies. Vascular endothelial growth factor (VEGF) pathway is among the important signal transducers in this process<sup>[29]</sup>. Several ligands including VEGF-A, -B, -C and -D initiate signals by binding cell surface receptor tyrosine kinases VEGF-R1 (also known as flt1), VEGF-R2 (also known as flk1) and VEGF-R3 (also known as flt4) and triggering down-stream cascades of cell proliferation and survival. VEGF pathway alterations are involved in pathogenesis of esophageal cancer<sup>[30]</sup>. VEGF-A expression is present in most ESCC and ranges between 24%-93% in different studies<sup>[31]</sup>. Moreover the over-expression of VEGF isoforms has been significantly correlated with poorer prognosis of ESCC<sup>[32,33]</sup>.

Bevacizumab is a monoclonal antibody targeting VEGF. It is used clinically in colon, breast, ovarian and lung adenocarcinomas. Its development in gastric and gastro-esophageal junction adenocarcinomas has progressed through phase III trials<sup>[34]</sup> but in squamous

cancers there is a reluctance to pursue development given safety issues with hemorrhage in squamous non-small cell lung cancer<sup>[35]</sup>. Small molecule TKI of VEGF receptor (VEGFR) have been studied in early trials that have included ESCC patients. Pazopanib, a TKI targeting VEGFR, platelet-derived growth factor receptor and c-Kit is already approved for the treatment of clear cell renal carcinoma. A phase I study combining it with carboplatin and paclitaxel in patients with various advanced cancers found the maximal tolerated dose to be 200 mg daily<sup>[36]</sup>. Among the patients in this trial there were 4 with esophageal carcinoma (histology not specified) and two of them had a complete response. The TKI sunitinib is evaluated in phase II studies as a single agent or in combination with paclitaxel in patients with advanced esophagogastric cancer of both histologies<sup>[37,38]</sup>. Another anti-VEGF TKI, sorafenib is studied as monotherapy. Responses so far have been reported in adenocarcinomas but only 2 patients with ESCC were included in this preliminary report<sup>[39]</sup>. A fourth anti-VEGFR TKI, vandetanib is in phase I development in combination with oxaliplatin and docetaxel in advanced esophageal and gastroesophageal junction adenocarcinomas and squamous carcinomas (trial number NCT00732745). It is evident from these data that the field of anti-VEGF therapy development in esophageal cancer is dominated by adenocarcinoma histology and few results for ESCC are available. It remains to be seen if further development, optimally aided by predictive markers, will be pursued in ESCC.

## ANTI-MTOR THERAPIES

Mammalian target of rapamycin (mTOR) is an intracellular serine/threonine kinase that plays important roles in RNA translation, cell proliferation and angiogenesis. Inhibition of mTOR by everolimus has shown activity and is used clinically in renal cell carcinoma<sup>[40]</sup>, pancreatic neuroendocrine tumors<sup>[41]</sup> and in breast cancer where it has been found to reverse tumor resistance to hormonal treatments<sup>[42]</sup>. In ESCC mTOR is reported to be activated in 25% of cases and co-relates with a lower degree of differentiation<sup>[43]</sup>. Another group found activation of mTOR in 50% to 70% of ESCC and showed worse overall and cancer specific survival in cases with activated mTOR compared with non-activated cases<sup>[44,45]</sup>. Proliferation of ESCC cell lines with activated mTOR was inhibited by everolimus *in vitro* and *in vivo* in mouse xenograft models<sup>[44]</sup>.

Very few clinical data on mTOR inhibitors in ESCC are available. In a phase I trial of everolimus a single esophageal cancer patient included (histology not reported) treated with 10 mg/d showed a marked response in a metastatic supraclavicular lymphadenopathy before dying of tumor-related hemorrhage<sup>[46]</sup>. An additional strategy for mTOR inhibitor development in ESCC would be their combination with other targeted treatments. As mTOR may be activated by the phosphati-

dylinositol 3-kinase (PI3K)/Akt pathway down-stream of receptor tyrosine kinases, a combined inhibition with inhibitors of these kinases may be advisable. Combination with direct inhibitors of PI3K could be an alternative. PI3K inhibitors are in development<sup>[47,48]</sup>. The hedgehog pathway is also co-operating with the PI3K/Akt pathway<sup>[49]</sup> and is activated in a sub-set of ESCC<sup>[50,51]</sup>. Hedgehog signaling is important in foregut development, a fact that may underline its importance in carcinogenesis in both squamous and adenocarcinomas of the esophagus<sup>[51]</sup>. Hedgehog pathway inhibitor vismodegib is used for the treatment of basal cell cutaneous carcinomas<sup>[52]</sup>. Preclinical studies have shown synergy of vismodegib with everolimus in esophageal adenocarcinomas<sup>[53]</sup>. A phase II study of the addition of vismodegib to FOLFOX chemotherapy in gastroesophageal adenocarcinomas is in progress<sup>[54]</sup>. Further development of mTOR inhibitors in ESCC enriched for activated mTOR with or without other targeted or chemotherapeutic treatments seems to be warranted.

## OTHER TARGETED THERAPIES

Hepatocyte growth factor/scatter factor (HGF) is the ligand for proto-oncogenic cell surface receptor c-Met. c-Met transduces proliferative and pro-angiogenic signals and has been related to prognosis of different malignancies<sup>[55,56]</sup>. A study in ESCC patients has shown that the serum level of HGF is higher than controls and correlates with levels of interleukin-8 and VEGF, both important mediators of angiogenesis<sup>[57]</sup>. HGF was also an independent prognostic factor for survival. Patients with higher than the median serum HGF had a median survival of 34 mo and a 2 year survival of 63% while those with serum HGF lower than the median had a median survival of only 15 mo and a 2 year survival of 37%<sup>[57]</sup>. Antibodies blocking this pathway could be a potential therapeutic strategy in ESCC. The small molecule kinase inhibitor against anaplastic lymphoma kinase crizotinib is concomitantly an inhibitor of c-Met and could be used to target this pathway.

Bryostatin-1 is an agent with antitumor activity *via* the inhibition of protein kinase C and has synergistic activity with chemotherapeutic agents such as paclitaxel<sup>[58]</sup>. In esophageal cancer a phase II trial of weekly paclitaxel and bryostatin-1 that included 22 patients demonstrated a response rate above 25% and up to 40% in the higher doses reached<sup>[59]</sup>. Nevertheless this trial has included only 2 patients with ESCC and had to close prematurely because of high rates of toxicities (myalgia) and two possibly treatment-related deaths. Bryostatin-1 analogs have been synthesized and could be alternatively developed if proved to have a better toxicity profile<sup>[60]</sup>.

Bortezomib is a proteasome inhibitor that is used in the treatment of myeloma and lymphoma. In pre-clinical studies in ESCC, bortezomib has shown activity by co-operating with both intrinsic and extrinsic pathways in

apoptosis induction<sup>[61,62]</sup>. A possible role of the drug in enhancing radiotherapy-induced cell death was suggested<sup>[62]</sup>. Despite the rational in targeting the proteasome as an anti-neoplastic treatment, in several solid tumors bortezomib has shown minimal activity. Thus an alternative approach with the identification and use of predictive biomarkers could be more effective if bortezomib (or other newer proteasome inhibitors such as carfilzomib<sup>[63]</sup>) were to be developed in ESCC.

The inducible form of the pathway enzyme cyclooxygenase (COX)-2 plays a role in the promotion of ESCC. Studies in preclinical models have shown that COX-2 inhibition has anti-tumor effects in ESCC cells<sup>[64]</sup>. These effects have been attributed to induction of apoptosis, inhibition of angiogenesis and suppression of invasion. In human ESCC, increased COX-2 expression correlates with reduced OS<sup>[65,66]</sup> and more aggressive tumor characteristics<sup>[67]</sup>. Furthermore, increased expression of EP2, the receptor for the COX-2 product prostaglandin PGE2, is associated with worse survival in patients with localized ESCC<sup>[68]</sup>. Dawson *et al.*<sup>[69]</sup> report a response rate of 54% in a phase I / II study of the COX-2 inhibitor celecoxib in combination with 5-FU/cisplatin/radiotherapy in 13 patients, with 3 of them having squamous histological type. This small number precludes any conclusions and no data are available in the metastatic setting. Moreover there are safety concerns with the coxib class of COX-2 inhibitors that limits their potential for further development. A recent study demonstrates that celecoxib antagonizes the cytotoxicity of cisplatin<sup>[70]</sup>, further complicating a putative development of coxibs in ESCC. Other non-steroidal anti-inflammatory drugs with a better safety record such as aspirin may be preferable, although many of them lack the selectivity of coxibs for COX-2 and inhibit concomitantly the constitutive form, COX-1.

Other opportunities for targeted treatments clearly exist based on detected abnormalities in ESCC cells. For example global histone H3 and H4 hypoacetylation was detected in tumors from patients with ESCC<sup>[71]</sup>. This may be the result of increased histone deacetylase 1 (HDAC1) expression in ESCC cells compared with adjacent normal tissues<sup>[72]</sup>. Inhibition of the expression of HDAC1 by RNAi resulted in enhanced radiosensitivity of ESCC cells *in vitro*. Histone deacetylase inhibitor vorinostat inhibited invasion of ESCC cells pretreated with tumor necrosis factor  $\alpha$  and transforming growth factor  $\beta$  in an *in vitro* assay<sup>[73]</sup>. The combination of vorinostat with the aforementioned proteasome inhibitor bortezomib further increased these invasion-inhibiting effects. Despite these pre-clinical encouraging data, no clinical data in ESCC are available for the time being regarding HDAC inhibitors.

Natural products contained in berries have been found to prevent ESCC in Fischer-344 rats treated with *N*-nitrosomethyl benzylamine (NMBA)<sup>[74]</sup>. This is a model of ESCC in which rats develop pre-neoplastic lesions passing from hyperplasia to dysplasia and finally to neo-

plasia (papillomas). In a clinical trial conducted in China, treatment with 60 mg daily of freeze-dried strawberries reversed mild to moderate dysplasia of esophagus<sup>[75]</sup>. Several carcinogenesis-involved molecules such as COX-2, nuclear factor  $\kappa$ B and targets of the mTOR pathway have been modified after this treatment. Whether the treatment could have beneficial effect in established carcinomas and what compound or compounds in the extracts provide the beneficial effect remains to be investigated.

## CONCLUSION

No targeted treatment agent has been introduced in the clinic for the treatment of ESCC until now. This relates to several factors that impede the clinical development of new drugs in ESCC. The rarity of these tumors not only makes the execution of trials with satisfactory numbers to extract conclusions more difficult but also obliges investigators to perform trials with both histologies in the organ or even including gastric cancer patients. As a result, effective treatments for only one of the histologies may be missed. The problem of patient recruitment will not be helped in the future as ESCC incidence (fortunately) decreases in western countries. Thus other solutions are needed including judicious “use” of the patient pool at hand. This implies that new agents to be entered in the clinical development face should have robust pre-clinical data supporting them and a molecular rational.

Another factor that may dilute possible positive results even within the same histology stems from the significant heterogeneity of cancer. This is probably of even greater importance for the development of targeted treatments than for chemotherapy agents. A promising strategy to overcome the heterogeneity barrier is the identification of prognostic markers which can help in the selection of patients. Such identification would lead in trials that will test a new targeted agent only in patients whose tumors over-express the target or express a mutated form of it. In some instances mere over-expression of the target is not enough or is not even present and demonstration of lesions in other proteins of the pathway(s) in which it participates is required for determination of sensitive sub-groups of a given tumor type. An illustrative example is anti-EGFR agents in colorectal cancer which are more effective in the sub-group of tumors with wild type Kras protein<sup>[76]</sup>. This protein is a down-stream effector of EGFR and when mutated blunts the activity of anti-EGFR agents because it is active even without receiving signals from the EGFR up-stream.

Related to the problem of tumor heterogeneity is the theory of tumor stem or tumor initiating cells. According to this theory only a generally small sub-set of neoplastic cells has the ability to propagate the tumor, while the bulk of the tumor derived from the sub-set of stem cells is less important because it lacks the capacity to proliferate indeterminably except if it acquires a stem cell phenotype<sup>[77]</sup>. In addition stem cells have been found to be drug

resistant and possess the ability to undergo epithelial to mesenchymal transition, a process endowing them with metastatic potential<sup>[78]</sup>. Thus a potential strategy for clinical development of targeted agents would be to determine the expression of their targets in stem cells and the dependence of those cells to these targets. By targeting tumor initiating cells one can argue that the anti-tumor effect would be more pronounced and durable.

## REFERENCES

- 1 **Thrift AP**, Pandeya N, Whiteman DC. Current status and future perspectives on the etiology of esophageal adenocarcinoma. *Front Oncol* 2012; **2**: 11 [PMID: 22655259 DOI: 10.3389/fonc.2012.00011]
- 2 **Haas SL**, Ye W, Löhr JM. Alcohol consumption and digestive tract cancer. *Curr Opin Clin Nutr Metab Care* 2012; **15**: 457-467 [PMID: 22797570 DOI: 10.1097/MCO.0b013e3283566699]
- 3 **Ribeiro U**, Posner MC, Safatle-Ribeiro AV, Reynolds JC. Risk factors for squamous cell carcinoma of the oesophagus. *Br J Surg* 1996; **83**: 1174-1185 [PMID: 8983603 DOI: 10.1002/bjs.1800830905]
- 4 **Mawhinney MR**, Glasgow RE. Current treatment options for the management of esophageal cancer. *Cancer Manag Res* 2012; **4**: 367-377 [PMID: 23152702]
- 5 **Scagliotti GV**, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemegaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. *J Clin Oncol* 2008; **26**: 3543-3551 [PMID: 18506025 DOI: 10.1200/JCO.2007.15.0375]
- 6 **Bang YJ**, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschhoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010; **376**: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]
- 7 **Hanawa M**, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, Ooi A. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. *Int J Cancer* 2006; **118**: 1173-1180 [PMID: 16161046 DOI: 10.1002/ijc.21454]
- 8 **Sunpaweravong P**, Sunpaweravong S, Puttawibul P, Mitarnun W, Zeng C, Barón AE, Franklin W, Said S, Varella-Garcia M. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. *J Cancer Res Clin Oncol* 2005; **131**: 111-119 [PMID: 15672286 DOI: 10.1007/s00432-004-0610-7]
- 9 **Guo M**, Liu S, Lu F. Gefitinib-sensitizing mutations in esophageal carcinoma. *N Engl J Med* 2006; **354**: 2193-2194 [PMID: 16707764 DOI: 10.1056/NEJMc052698]
- 10 **Guo M**, Liu S, Herman JG, Zhuang H, Lu F. Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450. *Cancer Biol Ther* 2006; **5**: 152-155 [PMID: 16357520 DOI: 10.4161/cbt.5.2.2318]
- 11 **Yang YL**, Xu KL, Zhou Y, Gao X, Chen LR. Correlation of epidermal growth factor receptor overexpression with increased epidermal growth factor receptor gene copy number in esophageal squamous cell carcinomas. *Chin Med J (Engl)* 2012; **125**: 450-454 [PMID: 22490401]
- 12 **Lorenzen S**, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler M, Grabowski P, Arnold D, Greten T, Müller L, Röthling N, Peschel C, Langer R, Lordick F. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. *Ann Oncol* 2009; **20**: 1667-1673 [PMID: 19549707 DOI: 10.1093/annonc/mdp069]
- 13 **Enzinger PC**, Burtness B, Hollis D, Niedzwiecki D, Ilson D, Benson AB, Mayer RJ, Goldberg RM. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. *J Clin Oncol* 2010; **28**: abstr 4006
- 14 **Zhang X**, Lu M, Gong J, Gao J, Wang X, Zhang X, Li J, Li Y, Li J, Zhou J, Lu Z, Shen L. Phase II study of nimotuzumab combination with paclitaxel and cisplatin as the first-line treatment in patients with local advanced or metastatic esophageal squamous cell cancer (ESCC): An interim analysis. *J Clin Oncol* 2012; **30**: abstr e14604
- 15 **Janmaat ML**, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, Van Groeningen C, Giaccone G. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. *J Clin Oncol* 2006; **24**: 1612-1619 [PMID: 16575012 DOI: 10.1200/JCO.2005.03.4900]
- 16 **Adelstein DJ**, Rodriguez CP, Rybicki LA, Ives DI, Rice TW. A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction. *Invest New Drugs* 2012; **30**: 1684-1689 [PMID: 21863238 DOI: 10.1007/s10637-011-9736-z]
- 17 **Ilson DH**, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, Capanu M, Miron B, Klimstra D. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. *Cancer* 2011; **117**: 1409-1414 [PMID: 21425140 DOI: 10.1002/cncr.25602]
- 18 **Piccatt-Gebhart MJ**, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lång I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschhoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med* 2005; **353**: 1659-1672 [PMID: 16236737 DOI: 10.1056/NEJMoa052306]
- 19 **Sato-Kuwabara Y**, Neves JI, Fregnani JH, Sallum RA, Soares FA. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. *BMC Cancer* 2009; **9**: 6 [PMID: 19128465 DOI: 10.1186/1471-2407-9-6]
- 20 **Mimura K**, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, Ooi A, Fujii H. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. *Br J Cancer* 2005; **92**: 1253-1260 [PMID: 15785739 DOI: 10.1038/sj.bjc.6602499]
- 21 **Dreilich M**, Wanders A, Brattström D, Bergström S, Hesselius P, Wagenius G, Bergqvist M. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. *Dis Esophagus* 2006; **19**: 224-231 [PMID: 16866851 DOI: 10.1111/j.1442-2050.2006.00570.x]
- 22 **Schoppmann SF**, Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, Maresch J, Zacherl J, Hejna M, Birner P. Expression of Her-2 in carcinomas of the esophagus. *Am J Surg Pathol* 2010; **34**: 1868-1873 [PMID: 21107094 DOI: 10.1097/PAS.0b013e3181f8be17]
- 23 **Kawaguchi Y**, Kono K, Mizukami Y, Mimura K, Fujii H. Mechanisms of escape from trastuzumab-mediated ADCC in esophageal squamous cell carcinoma: relation to susceptibility to perforin-granzyme. *Anticancer Res* 2009; **29**: 2137-2146

- [PMID: 19528474]
- 24 **Sato S**, Kajiyama Y, Sugano M, Iwanuma Y, Sonoue H, Matsumoto T, Sasai K, Tsurumaru M. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. *Int J Radiat Oncol Biol Phys* 2005; **61**: 203-211 [PMID: 15629613 DOI: 10.1016/j.ijrobp.2004.05.017]
  - 25 **Kawaguchi Y**, Kono K, Mimura K, Mitsui F, Sugai H, Akaike H, Fujii H. Targeting EGFR and HER-2 with cetuximab and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. *Br J Cancer* 2007; **97**: 494-501 [PMID: 17622245]
  - 26 **Mimura K**, Kono K, Hanawa M, Kanzaki M, Nakao A, Ooi A, Fujii H. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. *Clin Cancer Res* 2005; **11**: 4898-4904 [PMID: 16000588 DOI: 10.1158/1078-0432.CCR-04-2476]
  - 27 **Carson WE**, Roda J, Parihar R, Lamb T, Shapiro C, Bekaii-Saab T. Phase I trial of interleukin-12 with trastuzumab and paclitaxel in HER2-overexpressing malignancies. *J Clin Oncol* 2005; **23**: abstr 2531
  - 28 **Yap TA**, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. *J Clin Oncol* 2010; **28**: 3965-3972 [PMID: 20679611 DOI: 10.1200/JCO.2009.26.7278]
  - 29 **Eichmann A**, Simons M. VEGF signaling inside vascular endothelial cells and beyond. *Curr Opin Cell Biol* 2012; **24**: 188-193 [PMID: 22366328 DOI: 10.1016/j.ceb.2012.02.002]
  - 30 **Kleespies A**, Bruns CJ, Jauch KW. Clinical significance of VEGF-A, -C and -D expression in esophageal malignancies. *Onkologie* 2005; **28**: 281-288 [PMID: 15867486 DOI: 10.1159/000085198]
  - 31 **Kleespies A**, Guba M, Jauch KW, Bruns CJ. Vascular endothelial growth factor in esophageal cancer. *J Surg Oncol* 2004; **87**: 95-104 [PMID: 15282704 DOI: 10.1002/jso.20070]
  - 32 **Möbius C**, Freire J, Becker I, Feith M, Brücher BL, Hennig M, Siewert JR, Stein HJ. VEGF-C expression in squamous cell carcinoma and adenocarcinoma of the esophagus. *World J Surg* 2007; **31**: 1768-1772; discussion 1773-1774 [PMID: 17354029 DOI: 10.1007/s00268-006-0373-1]
  - 33 **Uchida S**, Shimada Y, Watanabe G, Tanaka H, Shibagaki I, Miyahara T, Ishigami S, Imamura M. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. *Br J Cancer* 1998; **77**: 1704-1709 [PMID: 9635853 DOI: 10.1038/bjc.1998.281]
  - 34 **Ohtsu A**, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. *J Clin Oncol* 2011; **29**: 3968-3976 [PMID: 21844504 DOI: 10.1200/JCO.2011.36.2236]
  - 35 **Hainsworth JD**, Fang L, Huang JE, Karlin D, Russell K, Faoro L, Azzoli C. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. *J Thorac Oncol* 2011; **6**: 109-114 [PMID: 21107290 DOI: 10.1097/JTO.0b013e3181f94ad4]
  - 36 **Burris HA**, Dowlati A, Moss RA, Infante JR, Jones SF, Spigel DR, Levinson KT, Lindquist D, Gainer SD, Dar MM, Suttle AB, Ball HA, Tan AR. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. *Mol Cancer Ther* 2012; **11**: 1820-1828 [PMID: 22679111 DOI: 10.1158/1535-7163.MCT-11-0997]
  - 37 **Bhinder AS**, Rose JS, Li X, Tahiri S, Clark D, Sammet S, Foy K, Rawale S, Kaumaya P, Bekaii-Saab T. A mechanistic radiographic and biologic phase II single-agent study of sunitinib in relapsed/refractory esophageal (E) and gastroesophageal (GE) cancers. *J Clin Oncol* 2010; **28**: abstr e14650
  - 38 **Schmitt JM**, Sommers SR, Fisher W, Ansari R, Robin E, Koneru K, McClean J, Liu Z, Tong Y, Hanna N. Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Group. *J Thorac Oncol* 2012; **7**: 760-763 [PMID: 22425927 DOI: 10.1097/JTO.0b013e31824abc7c]
  - 39 **Ibson D**, Janjigian YY, Shah MA, Kelsen DP, Tang LH, Campbell J, Fuqua L, Capanu M. Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and protracted stable disease observed in adenocarcinoma. *J Clin Oncol* 2011; **29**: abstr 4100
  - 40 **Motzer RJ**, Escudier B, Oudard S, Hutson TE, Porta C, Braccarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet* 2008; **372**: 449-456 [PMID: 18653228 DOI: 10.1016/S0140-6736(08)61039-9]
  - 41 **Yao JC**, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K. Everolimus for advanced pancreatic neuroendocrine tumors. *N Engl J Med* 2011; **364**: 514-523 [PMID: 21306238 DOI: 10.1056/NEJMoa1009290]
  - 42 **Baselga J**, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med* 2012; **366**: 520-529 [PMID: 22149876 DOI: 10.1056/NEJMoa1109653]
  - 43 **Boone J**, Ten Kate FJ, Offerhaus GJ, van Diest PJ, Rinkes IH, van Hillegersberg R. mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy? *J Clin Pathol* 2008; **61**: 909-913 [PMID: 18474542 DOI: 10.1136/jcp.2008.055772]
  - 44 **Hirashima K**, Baba Y, Watanabe M, Karashima RI, Sato N, Imamura Y, Nagai Y, Hayashi N, Iyama KI, Baba H. Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma. *Br J Cancer* 2012; **106**: 876-882 [PMID: 22333597 DOI: 10.1038/bjc.2012.36]
  - 45 **Hirashima K**, Baba Y, Watanabe M, Karashima R, Sato N, Imamura Y, Hiyoshi Y, Nagai Y, Hayashi N, Iyama K, Baba H. Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma. *Ann Surg Oncol* 2010; **17**: 2486-2493 [PMID: 20339946 DOI: 10.1245/s10434-010-1040-1]
  - 46 **Okamoto I**, Doi T, Ohtsu A, Miyazaki M, Tsuya A, Kurei K, Kobayashi K, Nakagawa K. Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. *Jpn J Clin Oncol* 2010; **40**: 17-23 [PMID: 19783551 DOI: 10.1093/jjco/hyp120]
  - 47 **Bruel A**, Logé C, Tazua ML, Ravache M, Le Guevel R, Guilloze C, Lohier JF, Oliveira Santos JS, Lozach O, Meijer L, Ruchaud S, Bénédicti H, Robert JM. Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3K $\alpha$  inhibitors. *Eur J Med Chem* 2012; **57**: 225-233 [PMID: 23063566 DOI: 10.1016/j.ejmech.2012.09.001]
  - 48 **Engelman JA**. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. *Nat Rev Cancer* 2009; **9**:

- 550-562 [PMID: 19629070 DOI: 10.1038/nrc2664]
- 49 **Wei L**, Xu Z. Cross-signaling among phosphoinositide-3 kinase, mitogen-activated protein kinase and sonic hedgehog pathways exists in esophageal cancer. *Int J Cancer* 2011; **129**: 275-284 [PMID: 20839260 DOI: 10.1002/ijc.25673]
  - 50 **Ma X**, Sheng T, Zhang Y, Zhang X, He J, Huang S, Chen K, Sultz J, Adegboyega PA, Zhang H, Xie J. Hedgehog signaling is activated in subsets of esophageal cancers. *Int J Cancer* 2006; **118**: 139-148 [PMID: 16003737 DOI: 10.1002/ijc.21295]
  - 51 **Yang L**, Wang LS, Chen XL, Gatalica Z, Qiu S, Liu Z, Stoner G, Zhang H, Weiss H, Xie J. Hedgehog signaling activation in the development of squamous cell carcinoma and adenocarcinoma of esophagus. *Int J Biochem Mol Biol* 2012; **3**: 46-57 [PMID: 22509480]
  - 52 **Dlugosz A**, Agrawal S, Kirkpatrick P. Vismodegib. *Nat Rev Drug Discov* 2012; **11**: 437-438 [PMID: 22653209 DOI: 10.1038/nrd3753]
  - 53 **Wang Y**, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, Lee DF, Hsu JM, Huo L, Labaff AM, Liu D, Huang TH, Lai CC, Tsai FJ, Chang WC, Chen CH, Wu TT, Buttar NS, Wang KK, Wu Y, Wang H, Ajani J, Hung MC. The crosstalk of mTOR/S6K1 and Hedgehog pathways. *Cancer Cell* 2012; **21**: 374-387 [PMID: 22439934 DOI: 10.1016/j.ccr.2011.12.028]
  - 54 **Cohen DJ**, Liebes L, Xu R, Takebe N, Sparano JA. A randomized, double-blind placebo-controlled phase II study of FOLFOX with or without GDC-0449 (vismodegib) in patients with advanced gastric and gastroesophageal junction carcinoma (NCI 8376). *J Clin Oncol* 2011; **29**: abstr TPS173
  - 55 **Gohji K**, Nomi M, Niitani Y, Kitazawa S, Fujii A, Katsuoka Y, Nakajima M. Independent prognostic value of serum hepatocyte growth factor in bladder cancer. *J Clin Oncol* 2000; **18**: 2963-2971 [PMID: 10944129]
  - 56 **Naughton M**, Picus J, Zhu X, Catalona WJ, Vollmer RT, Humphrey PA. Scatter factor- hepatocyte growth factor elevation in the serum of patients with prostate cancer. *J Urol* 2001; **165**: 1325-1328 [PMID: 11257710 DOI: 10.1016/S0022-5347(01)69893-8]
  - 57 **Ren Y**, Cao B, Law S, Xie Y, Lee PY, Cheung L, Chen Y, Huang X, Chan HM, Zhao P, Luk J, Vande Woude G, Wong J. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. *Clin Cancer Res* 2005; **11**: 6190-6197 [PMID: 16144920 DOI: 10.1158/1078-0432.CCR-04-2553]
  - 58 **Koutcher JA**, Motwani M, Zakian KL, Li XK, Matei C, Dyke JP, Ballon D, Yoo HH, Schwartz GK. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow. *Clin Cancer Res* 2000; **6**: 1498-1507 [PMID: 10778982]
  - 59 **Ku GY**, Ilson DH, Schwartz LH, Capanu M, O'Reilly E, Shah MA, Kelsen DP, Schwartz GK. Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. *Cancer Chemother Pharmacol* 2008; **62**: 875-880 [PMID: 18270704 DOI: 10.1007/s00280-008-0677-y]
  - 60 **Wender PA**, Horan JC, Verma VA. Total synthesis and initial biological evaluation of new B-ring-modified bryostatin analogs. *Org Lett* 2006; **8**: 5299-5302 [PMID: 17078702 DOI: 10.1021/ol0620904]
  - 61 **Lioni M**, Noma K, Snyder A, Klein-Szanto A, Diehl JA, Rustgi AK, Herlyn M, Smalley KS. Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. *Mol Cancer Ther* 2008; **7**: 2866-2875 [PMID: 18790767 DOI: 10.1158/1535-7163.MCT-08-0391]
  - 62 **Seki N**, Toh U, Sayers TJ, Fujii T, Miyagi M, Akagi Y, Kusukawa J, Kage M, Shirouzu K, Yamana H. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways. *Mol Cancer Ther* 2010; **9**: 1842-1851 [PMID: 20515944 DOI: 10.1158/1535-7163.MCT-09-0918]
  - 63 **Fostier K**, De Becker A, Schots R. Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma. *Oncotargets Ther* 2012; **5**: 237-244 [PMID: 23055749]
  - 64 **Zhang L**, Wu YD, Li P, Tu J, Niu YL, Xu CM, Zhang ST. Effects of cyclooxygenase-2 on human esophageal squamous cell carcinoma. *World J Gastroenterol* 2011; **17**: 4572-4580 [PMID: 22147962 DOI: 10.3748/wjg.v17.i41.4572]
  - 65 **Li L**, Zhao J, Wu Z, Wang G, Chen G. Meta-analysis: clinicopathological and prognostic significance of cyclooxygenase-2 expression on oesophageal squamous cell carcinoma. *Aliment Pharmacol Ther* 2009; **30**: 589-596 [PMID: 19549265 DOI: 10.1111/j.1365-2036.2009.04069.x]
  - 66 **Liu JF**, Jamieson G, Wu TC, Zhang SW, Wang QZ, Drew P. Cyclooxygenase-2 expression in squamous cell carcinoma of the esophagus. *Dis Esophagus* 2006; **19**: 350-354 [PMID: 16984531 DOI: 10.1111/j.1442-2050.2006.00594.x]
  - 67 **Kase S**, Osaki M, Honjo S, Adachi H, Tsujitani S, Kaibara N, Ito H. Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas. *Virchows Arch* 2003; **442**: 129-135 [PMID: 12596063]
  - 68 **Kuo KT**, Wang HW, Chou TY, Hsu WH, Hsu HS, Lin CH, Wang LS. Prognostic role of PGE2 receptor EP2 in esophageal squamous cell carcinoma. *Ann Surg Oncol* 2009; **16**: 352-360 [PMID: 19050969 DOI: 10.1245/s10434-008-0242-2]
  - 69 **Dawson SJ**, Michael M, Biagi J, Foo KF, Jefford M, Ngan SY, Leong T, Hui A, Milner AD, Thomas RJ, Zalberg JR. A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. *Invest New Drugs* 2007; **25**: 123-129 [PMID: 17053988 DOI: 10.1007/s10637-006-9016-5]
  - 70 **Yu L**, Chen M, Li Z, Wen J, Fu J, Guo D, Jiang Y, Wu S, Cho CH, Liu S. Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation. *Mol Pharmacol* 2011; **79**: 608-617 [PMID: 21177414 DOI: 10.1124/mol.110.069393]
  - 71 **Chen C**, Zhao M, Yin N, He B, Wang B, Yuan Y, Yu F, Hu J, Yin B, Lu Q. Abnormal histone acetylation and methylation levels in esophageal squamous cell carcinomas. *Cancer Invest* 2011; **29**: 548-556 [PMID: 21843048 DOI: 10.3109/07357907.2011.597810]
  - 72 **Zhang B**, Wang Y, Pang X. Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression. *Med Oncol* 2012; **29**: 340-348 [PMID: 20464640 DOI: 10.1007/s12032-010-9559-3]
  - 73 **Taylor MD**, Liu Y, Nagji AS, Theodosakis N, Jones DR. Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells. *J Thorac Cardiovasc Surg* 2010; **139**: 1224-132, 1232.e1 [PMID: 20412959 DOI: 10.1016/j.jtcvs.2010.01.039]
  - 74 **Stoner GD**, Chen T, Kresty LA, Aziz RM, Reinemann T, Nines R. Protection against esophageal cancer in rodents with lyophilized berries: potential mechanisms. *Nutr Cancer* 2006; **54**: 33-46 [PMID: 16800771 DOI: 10.1207/s15327914nc5401\_5]
  - 75 **Chen T**, Yan F, Qian J, Guo M, Zhang H, Tang X, Chen F, Stoner GD, Wang X. Randomized phase II trial of lyophilized strawberries in patients with dysplastic precancerous lesions of the esophagus. *Cancer Prev Res (Phila)* 2012; **5**: 41-50 [PMID: 22135048 DOI: 10.1158/1940-6207.CAPR-11-0469]
  - 76 **Qiu LX**, Mao C, Zhang J, Zhu XD, Liao RY, Xue K, Li J, Chen Q. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab:

a meta-analysis of 22 studies. *Eur J Cancer* 2010; **46**: 2781-2787 [PMID: 20580219 DOI: 10.1016/j.ejca.2010.05.022]

- 77 **Valent P**, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wöhrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE,

Andreeff M, Eaves C. Cancer stem cell definitions and terminology: the devil is in the details. *Nat Rev Cancer* 2012; **12**: 767-775 [PMID: 23051844 DOI: 10.1038/nrc3368]

- 78 **Kalluri R**, Weinberg RA. The basics of epithelial-mesenchymal transition. *J Clin Invest* 2009; **119**: 1420-1428 [PMID: 19487818 DOI: 10.1172/JCI39104]

**P-Reviewer** Deans C **S-Editor** Huang XZ **L-Editor** A  
**E-Editor** Yan JL



## RAS signaling pathways, mutations and their role in colorectal cancer

Kypros Zenonos, Katy Kyprianou

Kypros Zenonos, Katy Kyprianou, College of Medical and Dental Sciences, University of Birmingham, Edgbaston B15 2TT, United Kingdom

**Author contributions:** Both authors contributed equally in researching the subject; Zenonos K wrote the report and Kyprianou K edited it.

**Correspondence to:** Dr. Kypros Zenonos, College of Medical and Dental Sciences, University of Birmingham, Flat 2, 250 High Street, Birmingham B17 9PT, United Kingdom. [kxz908@bham.ac.uk](mailto:kxz908@bham.ac.uk)

Telephone: +44-776-6737215 Fax: +44-776-6737215

Received: February 16, 2013 Revised: March 26, 2013

Accepted: April 10, 2013

Published online: May 15, 2013

oncogene operates physiologically. It also describes the mutations in these pathways that lead to colorectal cancer (CRC), as well as other mutations outside these cascades affecting RAS function and also leading to CRC. The prognostic value of each mutation is assessed and linked to response rates to available biological treatments. Monoclonal antibodies under development are also briefly discussed.

Zenonos K, Kyprianou K. RAS signaling pathways, mutations and their role in colorectal cancer. *World J Gastrointest Oncol* 2013; 5(5): 97-101 Available from: URL: <http://www.wjgnet.com/1948-5204/full/v5/i5/97.htm> DOI: <http://dx.doi.org/10.4251/wjgo.v5.i5.97>

### Abstract

Two of the main cellular pathways in which the RAS protein operates are the mitogen-activated protein kinases (MAPK) and phosphoinositide-3 kinase (PI3K) pathways. In a normal cell, these are important in controlling several functions, such as cell growth and survival. It becomes self-evident that these events will be disrupted in a malignant cell with a deregulated MAPK or PI3K pathway. Mutations in genes involved in these pathways and interacting with RAS, as well as RAS itself will be discussed. The second part of this review concentrates on how crucial RAS signaling is in colorectal cancer progression, with references to treatment response and prognosis when RAS or other related mutations are present.

© 2013 Baishideng. All rights reserved.

**Key words:** Genes; RAS; Colorectal neoplasms; Therapeutics; Mitogen-activated protein kinase signaling system

**Core tip:** This review outlines clearly the normal function of the mitogen-activated protein kinases and phosphoinositide-3 kinase cascades, in which the RAS proto-

### MITOGEN-ACTIVATED PROTEIN KINASES SIGNALING CASCADE

Two of the main cellular pathways in which the RAS protein operates are the mitogen-activated protein kinases (MAPK) and phosphoinositide-3 kinase (PI3K) pathways. In a normal cell, these are important in controlling several functions, such as cell growth and survival<sup>[1,2]</sup>. The first step towards activating this pathway occurs when a ligand binds to a receptor tyrosine kinase (RTK). For example, a well known ligand is epidermal growth factor (EGF), whose receptor is EGFR. Before being able to bind EGFR, EGF must first be released from the cell surface membrane where it resides. This is achieved by means of the TACE/ADAM-17 enzyme, which is particularly capable of cleaving transforming growth factor- $\alpha$  and amphiregulin, two of the ligands belonging to the EGF family<sup>[3]</sup>.

Following ligand binding, the receptor becomes dimerised and phosphorylated<sup>[4]</sup>. Next, a complex of proteins is established within the cell, with growth factor receptor-bound protein 2 (GRB2) becoming attached to the receptor, whilst being bound by son of sevenless

(SOS). Then the SOS protein, whilst still attached to GRB2, binds RAS as well. It should be noted here that there are several subtypes of the RAS protein, such as HRAS, NRAS and KRAS, but the most important one with regards to colorectal carcinogenesis is the latter, followed by NRAS<sup>[1]</sup>.

After the attachment of SOS to RAS, SOS shows guanine nucleotide exchange factor activity. This means that SOS is capable of displacing guanosine diphosphate (GDP) molecules from RAS and thus allowing guanosine triphosphate (GTP) molecules to bind and activate it. Active GTP-RAS is able to recruit the RAF proteins (A-RAF, B-RAF and C-RAF) to the cell surface. The RAF proteins are normally bound to, and therefore inhibited by, the 14-3-3 proteins in the cytosol. However, after binding to GTP-RAS, the RAF proteins are released from the 14-3-3 proteins and are therefore activated; they pair up amongst them and form heterodimers, which are then capable of binding and activating the KSR1 enzyme<sup>[1]</sup>.

The KSR1 enzyme is a relay hub connecting RAF heterodimers with the MEK protein. Hence, RAF proteins are able to phosphorylate and activate MEK, which in turn phosphorylates and activates ERK. ERK then enters the cell nucleus to activate a range of transcription factors, such as Jun and Fos<sup>[1]</sup>; these bind to the AP-1 DNA domain of the nucleus and transcribe genes involved in cell proliferation<sup>[5]</sup>.

The above process is entirely normal in a healthy cell, and is terminated by means of RAS-GTPase activating (GAP) proteins. As their name suggests, these proteins activate GTPase enzymes found within RAS, which hydrolyse GTP to GDP and therefore switch RAS off<sup>[1]</sup>.

---

## MUTATIONS RELATIVE TO THE MAPK PATHWAY

---

### RAS mutations

One of the most frequent ways in which the MAPK is set to overdrive is by a mutation in the RAS protein; mutations in the KRAS protein are found in about 40% of all colorectal cancer (CRC) cases, whereas NRAS mutations are less common, having a frequency of 5%. Both in KRAS and NRAS, the most typical mutations are found at codons 12, most of the times, 13 and 61 (the latter being rarely affected). These mutations are sometimes present in early adenomas and in cells with minimal potential to develop a malignancy. However, they are also thought to enhance the malignant behaviour of cells with advanced CRC; both *in vitro* and animal studies indicate that silencing these mutated codons leads to attenuation of the tumourigenic growth properties of the affected cells<sup>[6]</sup>.

In molecular terms, mutations in these three KRAS/NRAS codons may lead to conformational changes so that the RAS-GAP protein cannot activate the inherent GTPase enzyme anymore. As a result, the GTP molecules are not hydrolysed and instead they maintain RAS continuously in its active state, thus causing protumorigenic

effects by amplifying signaling in the MAPK pathway<sup>[7]</sup>.

### BRAF mutations

BRAF can also be mutated in the MAPK pathway, and this appears to happen in about 5%-10% of all colon cancer cases<sup>[6]</sup>. The commonest BRAF mutation amongst all cancers, including colorectal, is the V600E mutation. This occurs when adenine replaces thymine at nucleotide 1799. Consequently, glutamic acid (E) substitutes valine (V) at codon 600, hence the name of the mutation<sup>[8,9]</sup>.

Two basic models were proposed to explain how CRCs arise, and BRAF mutations occur in both of them. The first model proposed by Fearon and Vogelstein in 1990 suggested that CRC is a result of multiple adenomatous lesions progressing to carcinomas, following several somatic and inherited gene alterations<sup>[10]</sup>. Apparently, this is what happens in the majority of the cases<sup>[11]</sup>. In this model, the mutation of adenomatous polyposis coli (APC) leading to initial formation of the polyps is of paramount importance<sup>[12]</sup>.

The second model, true in approximately 15% of all CRC cases<sup>[6]</sup>, holds that CRC is caused by mutation of mismatch repair (*MMR*) genes, which normally fix errors in DNA replication. Hence the mutations result in replicative errors not being corrected and therefore microsatellites (short DNA repetitions) start accumulating or become abnormally short, leading to microsatellite instability (MSI)<sup>[13]</sup> and colorectal carcinogenesis. Inactivation of *MMR* genes can be observed in the hereditary non-polyposis CRC (HNPCC) syndrome, but it usually occurs epigenetically; epigenetic inactivation most often involves the hypermethylation of MutL homolog 1 (*MLH1*), one of the *MMR* genes, and falls under a category of colorectal tumours called CpG island methylator phenotype (CIMP). CIMP tumours have a specific histological appearance, termed sessile serrated adenomas (SSAs). BRAF mutations are very frequent in SSAs, but not so frequent in HNPCC. Overall, they are mostly found amongst sporadic, high in MSI (MSI-H) colorectal tumours<sup>[6]</sup>.

In any case, a BRAF mutation will lead to increased kinase activity and therefore increased downstream signaling in the MAPK cascade<sup>[6]</sup>.

### EGFR and other RTK mutations

EGFR (*HER-1*) gene amplifications or point mutations may cause an up-regulation of the receptor, thus increasing the probability of its activation by EGF binding and thus increasing signaling. However, such events are quite uncommon and appear in less than 5% of CRCs<sup>[14]</sup>. The human epidermal growth factor receptor 2 (*HER-2*)/neu receptor can also be overexpressed; though the evidence is inconsistent and ranges are anywhere between 0% and 83%, it is unlikely that this is a major determinant of colorectal tumorigenesis<sup>[15]</sup>.

---

## PI3K SIGNALING CASCADE

---

The other main pathway in which RAS is involved is the

PI3K pathway. This is a very complex pathway, therefore only some of its key elements will be mentioned here. Just like in the case of the MAPK pathway, various growth factors initially bind on receptor tyrosine kinases, leading to their dimerisation and autophosphorylation. The next stage involves PI3Ks. There are three different classes of PI3Ks, but the most important class in human cancer is IA. The regulatory subunit of this class, p85, attaches to phosphotyrosine residues and/or other adaptors found on the RTKs. As a result, p110, the catalytic subunit of the PI3Ks is disinhibited and phosphorylates PIP2 to PIP3<sup>[2]</sup>. RAS can also activate the pathway physiologically by directly binding p110<sup>[16]</sup>. Conversely, the tumour suppressor protein PTEN dephosphorylates PIP3 back to PIP2, thus terminating signaling<sup>[2]</sup>.

Once PIP3 is formed, it recruits PDK1 and AKT kinases and brings them in close proximity. PDK1 phosphorylates AKT. Consequently, AKT becomes activated and generates several signals, the details of which are probably unrelated to this topic. These signals essentially contribute to cellular growth and evasion of apoptosis<sup>[2]</sup>.

## MUTATIONS RELATIVE TO THE PI3K PATHWAY

### PIK3CA mutation

*PIK3CA* is the gene encoding for P110 $\alpha$ . Mutation of RAS often coexists with mutations at exons 9 and 20 of *PIK3CA*<sup>[17]</sup>. It has been hypothesised that, when RAS is mutated, it can no longer bind the physiological form of P110 $\alpha$  efficiently. This necessitates the mutation of *PIK3CA*, which apparently will encode for a truncated version of P110 $\alpha$ , on which the mutant RAS will be able to bind effectively. The estimated frequency of *PIK3CA* mutations in CRC is 15%-25%, and these may lead to increased PI3K activity<sup>[6]</sup>.

### Phosphatase and tensin homolog mutation

Nonsense mutations and deletions in the phosphatase and tensin homolog (*PTEN*) gene makes the PTEN protein unable to convert PIP3 to PIP2, thus it can no longer act as an antagonist to PI3K signaling. This mutation is cardinal to the manifestation of Cowden syndrome, as it appears in 85% of all its cases. Cowden syndrome is an autosomal dominant disorder that predisposes to multiple cancers, including colorectal. Overall, it is estimated that *PTEN* is mutated in 10%-20% of all CRCs<sup>[6]</sup>.

## OTHER MUTATIONS AFFECTING RAS SIGNALING

### Neurofibromin 1 mutations

The neurofibromin 1 (*NF1*) gene is responsible for causing the genetic disease neurofibromatosis type 1. *NF1* acts as a negative regulator of RAS because it transcribes neurofibromin, a GAP; as mentioned above, these proteins hydrolyse RAS-bound GTP to GDP, therefore inactivating RAS. It has been suggested that *NF1* may play a

role in colorectal carcinogenesis when mutated, because it can no longer inhibit RAS signaling effectively. Indeed some studies have found increased *NF1* mutations in malignant colorectal tissue<sup>[18,19]</sup>, and in concurrence with *KRAS* mutations as well. Having said that, *NF1* mutations may also occur with wild type *KRAS*. In addition, one study found that the majority of *NF1* mutations were actually concurrent with *BRAF* mutations, especially in MSI-H tumours<sup>[18]</sup>. Paradoxically, a more recent *in vitro* study observed that the mitogen-activated protein kinase (MAPK) pathway signaling was upregulated in malignant colorectal cells with wild type *BRAF* and a knocked out *NF1* gene<sup>[20]</sup>. Therefore, the role of *NF1* in human colorectal carcinogenesis remains largely controversial.

The inverse relationship between CRC and neurofibromatosis type 1 is also evident; rarely, children with homozygous deficiency of the *MLH1* gene, which leads to HNPCC, exhibit features of neurofibromatosis type 1<sup>[21]</sup>.

### RASSF mutations

The RASSF is a family of ten genes (*RASSF1-10*), members of which seem to act as tumour suppressors. An emerging body of evidence indicates that they can stimulate growth arrest and proapoptotic signals mediated by RAS. The exact way they achieve this is still unclear; there are suggestions that there is a domain in RAS which *RASSF* can bind, and indeed this holds true to date for *RASSF1*, *RASSF2*, *RASSF4* and *RASSF5*. *RASSF1A* is one of the most well studied members of the family<sup>[22]</sup>, and it has been said that it either binds farnesylated *KRAS* directly<sup>[18,23]</sup> or it has to form a heterodimer with *RASSF5* before is able to bind RAS<sup>[18,24]</sup>.

Silencing of *RASSF1A* may occur when a specific sequence on the gene, the CpG island promoter region [*i.e.*, a region rich in cytosine (C) and guanine (G) nucleobases linked by phosphodiester (p) bonds] is methylated. This event is regarded to be a major contributor to early CRC development, ranging from 12% to 81% amongst different studies. Methylation can also affect *RASSF2* and *RASSF5* in the context of CRC. Nevertheless, exactly how they bring about malignancy is currently under investigation<sup>[22]</sup>.

## HOW IMPORTANT RAS SIGNALING IS FOR CRC

In order to evaluate the importance of RAS signaling, it is reasonable to examine how RAS and associated mutations behave in the clinical setting; whether they respond to current treatments, and how good the prognosis is when such mutations are evident.

### Issues with KRAS

Screening for *KRAS* mutation is the only widely used and accepted prognostic tool to decide eligibility for monoclonal antibody therapy<sup>[25,26]</sup>. This is largely because, the only molecular treatment currently licensed to be used in clinical practice is anti-EGFR therapy<sup>[26]</sup>. Hence, the

identification of a *KRAS* mutation is used as a means of exclusion from anti-EGFR therapy. The rationale for this is that since the MAPK pathway signaling is upregulated by a constitutively active KRAS protein, it is worthless to try and block the EGFR since MAPK signaling is no longer dependent on the activation of the receptor<sup>[25]</sup>.

However, the above notion, though probably true most of the times, is not universally accepted. Although mutant *KRAS*, especially the G12V mutation, is often associated with poor response to anti-EGFR agents<sup>[26]</sup>, some studies have not found the same results. Several clinical studies observed that patients with a p.G13D (codon 13) mutation in *KRAS* actually responded to treatment with cetuximab, as they had increased progression-free and overall survival compared to those on best supportive care or chemotherapy alone. This is a conclusion not to be ignored, because p.G13D positive patients are often refused administration of cetuximab (based on the rationale described above), albeit they could potentially benefit from it. Hence, further prospective clinical trials should be performed to confirm these data, since the value of the *KRAS* p.G13D mutation as a negative predictive biomarker is still contradictory<sup>[27]</sup>.

In addition, regarding metastatic CRC, there is also a question of whether the primary or the metastatic lesion should be analysed for genetic mutations. Some researchers postulate that there is no difference between the two, whereas others report significant variations. It is also argued that the genetic profile of the metastatic lesion is what matters most, because it is the metastasis that causes the bulk of the morbidity and mortality related to the disease. These hypotheses may again have ethical implications. In a hypothetical scenario, a patient has a genetic variation between his primary and metastatic lesions; the majority of his metastatic cells carry the wild type *KRAS* gene, but the primary lesion has mutant alleles. Based on the latter, he is wrongfully denied potentially beneficial anti-EGFR therapy, if indeed the metastasis is what's causing the major problem<sup>[26]</sup>.

Finally, there is uncertainty regarding how many and which *KRAS* codons should be screened, as well as issues with cost-effectiveness<sup>[26]</sup>.

### Clinical status of other mutations

There are a great number of cases with wild type *KRAS* tumours which fail to respond to anti-EGFR therapy. This of course might happen because there are other mutations disrupting the MAPK pathway. These may include mutations in other regions of the *KRAS* gene which are not commonly tested. Indeed, the majority of clinical trials regarding *KRAS* mutations in CRC involved screening codons 12 and 13 only, whereas there are reported mutations in exons 3 and 4 as well<sup>[26]</sup>. *NRAS* also becomes mutated occasionally.

*BRAF* mutation is associated with very poor prognosis as it does not respond to anti-EGFR therapy. In fact, in a study performed by Di Nicolantonio *et al*<sup>[28]</sup>, it was observed that none of the patients with a V600E

*BRAF* mutation responded to either cetuximab or panitumumab. *BRAF* mutations are also mutually exclusive with *KRAS* mutations, *i.e.*, these two do not occur together<sup>[18,25-28]</sup>. This means that if mutant *KRAS* is identified in a patient, there is no point of screening for *BRAF* as well. It is rather more useful to screen for *KRAS* first, since some particular mutations, as already discussed, may validate the use of anti-EGFR therapy. This is not the case for *BRAF*, where there is no response to monoclonal antibodies whatsoever. Hence, as a prognostic biomarker, *BRAF* can only be used to indicate complete insensitivity to anti-EGFR agents.

Contrary to *BRAF*, *PIK3CA* and *PTEN* are not mutually exclusive to *KRAS*<sup>[29]</sup>. Loss of function of *PTEN* or mutation in *PIK3CA* is often associated with poorer response to cetuximab or panitumumab, as expected. However, there is no standard, reliable scoring system by which *PTEN* loss can be detected, thus making it an unsuitable prognostic biomarker. At the same time, the data regarding *PIK3CA* mutations is not uniform, as some studies report no overall difference in 5-year survival for patients with *PIK3CA* mutation, whilst others report positive response to cetuximab<sup>[29]</sup>.

### The future

Most patients responding well to current treatments are essentially those who only have EGFR upregulation. All the other mutations necessitate the discovery of agents that can block RAS signaling further down the pathway. Such a discovery will render any specific gene alteration irrelevant. Indeed, there has been a development of a *RAF* inhibitor, called PLX4032, which showed inhibition of *RAF* in melanoma, but had little success with CRC cells<sup>[30]</sup>. Similarly, AZD6244, a *MEK* inhibitor which recently entered phase 2 trials for CRC showed no significant advantage over chemotherapy<sup>[26]</sup>.

## CONCLUSION

It has recently been said that the MAPK and PI3K cascades are important to carcinogenesis and progression of CRC<sup>[25]</sup>. Apart from *KRAS* mutations, which are the main reason why anti-EGFR agents fail, several other genes related to RAS signaling also contribute to CRC manifestation and, some more than others, to anti-EGFR therapy insensitivity. If nothing else, *KRAS* and *BRAF* mutations can be used as negative biomarkers to identify patients who will not benefit from cetuximab and panitumumab. Nevertheless, as mentioned earlier, we do not know everything, as there are still several controversies in the data regarding the clinical status of some mutations, as in the case of p.G13D *KRAS*, *PIK3CA* and others. These indicate that there is a need to perform larger clinical trials that will minimise statistical error and will find out what exactly happens in these cases. In doing so, perhaps a deeper insight will be gained into the molecular mechanisms giving rise to CRC, thus allowing for pioneering pharmacological agents to be successfully developed.

## REFERENCES

- 1 **Nandan MO**, Yang VW. An Update on the Biology of RAS/RAF Mutations in Colorectal Cancer. *Curr Colorectal Cancer Rep* 2011; **7**: 113-120 [PMID: 21625338 DOI: 10.1007/s11888-011-0086-1]
- 2 **Courtney KD**, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. *J Clin Oncol* 2010; **28**: 1075-1083 [PMID: 20085938 DOI: 10.1200/JCO.2009.25.3641]
- 3 **Merchant NB**, Voskresensky I, Rogers CM, Lafleur B, Dempsey PJ, Graves-Deal R, Revetta F, Foutch AC, Rothenberg ML, Washington MK, Coffey RJ. TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. *Clin Cancer Res* 2008; **14**: 1182-1191 [PMID: 18281553 DOI: 10.1158/1078-0432.CCR-07-1216]
- 4 **Reuter CW**, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? *Blood* 2000; **96**: 1655-1669 [PMID: 10961860]
- 5 **Ubeda M**, Vallejo M, Habener JF. CHOP enhancement of gene transcription by interactions with Jun/Fos AP-1 complex proteins. *Mol Cell Biol* 1999; **19**: 7589-7599 [PMID: 10523647]
- 6 **Fearon ER**. Molecular genetics of colorectal cancer. *Annu Rev Pathol* 2011; **6**: 479-507 [PMID: 21090969 DOI: 10.1146/annurev-pathol-011110-130235]
- 7 **Mitin N**, Rossman KL, Der CJ. Signaling interplay in Ras superfamily function. *Curr Biol* 2005; **15**: R563-R574 [PMID: 16051167 DOI: 10.1016/j.cub.2005.07.010]
- 8 **Tan YH**, Liu Y, Eu KW, Ang PW, Li WQ, Salto-Tellez M, Iacopetta B, Soong R. Detection of BRAF V600E mutation by pyrosequencing. *Pathology* 2008; **40**: 295-298 [PMID: 18428050 DOI: 10.1080/00313020801911512]
- 9 **Dhomen N**, Marais R. New insight into BRAF mutations in cancer. *Curr Opin Genet Dev* 2007; **17**: 31-39 [PMID: 17208430 DOI: 10.1016/j.gde.2006.12.005]
- 10 **Fearon ER**, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell* 1990; **61**: 759-767 [PMID: 2188735 DOI: 10.1016/0092-8674(90)90186-I]
- 11 **Ballinger AB**, Anggiansah C. Colorectal cancer. *BMJ* 2007; **335**: 715-718 [PMID: 17916855 DOI: 10.1136/bmj.39321.527384.BE]
- 12 **Markowitz SD**, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. *N Engl J Med* 2009; **361**: 2449-2460 [PMID: 20018966 DOI: 10.1056/NEJMra0804588]
- 13 **Oki E**, Oda S, Maehara Y, Sugimachi K. Mutated gene-specific phenotypes of dinucleotide repeat instability in human colorectal carcinoma cell lines deficient in DNA mismatch repair. *Oncogene* 1999; **18**: 2143-2147 [PMID: 10321739 DOI: 10.1038/sj.onc.1202583]
- 14 **Heinemann V**, Stintzing S, Kirchner T, Boeck S, Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. *Cancer Treat Rev* 2009; **35**: 262-271 [PMID: 19117687 DOI: 10.1016/j.ctrv.2008.11.005]
- 15 **Schuell B**, Gruenberger T, Scheithauer W, Zielinski Ch, Wrba F. HER 2/neu protein expression in colorectal cancer. *BMC Cancer* 2006; **6**: 123 [PMID: 16681853 DOI: 10.1186/1471-2407-6-123]
- 16 **Shaw RJ**, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. *Nature* 2006; **441**: 424-430 [PMID: 16724053 DOI: 10.1038/nature04869]
- 17 **Baldus SE**, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. *Clin Cancer Res* 2010; **16**: 790-799 [PMID: 20103678 DOI: 10.1158/1078-0432.CCR-09-2446]
- 18 **Ahlquist T**, Bottillo I, Danielsen SA, Meling GI, Rognum TO, Lind GE, Dallapiccola B, Lothe RA. RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A. *Neoplasia* 2008; **10**: 680-686, 686 [PMID: 18592002]
- 19 **Cacev T**, Radosevic S, Spaventi R, Pavelic K, Kapitanovic S. NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer. *Gut* 2005; **54**: 1129-1135 [PMID: 15840687 DOI: 10.1136/gut.2004.053348]
- 20 **Ali MA**, Sjoblom T. Core Ras pathway signaling in human colorectal cancers revealed by isogenic modelling of NF1, KRAS and BRAF. *Eur J Cancer* 2012; **48**: 118 [DOI: 10.1016/S0959-8049(12)71162-0]
- 21 **Gallinger S**, Aronson M, Shayan K, Ratcliffe EM, Gerstle JT, Parkin PC, Rothenmund H, Croitoru M, Baumann E, Durie PR, Weksberg R, Pollett A, Riddell RH, Ngan BY, Cutz E, Lagarde AE, Chan HS. Gastrointestinal cancers and neurofibromatosis type 1 features in children with a germline homozygous MLH1 mutation. *Gastroenterology* 2004; **126**: 576-585 [PMID: 14762794 DOI: 10.1053/j.gastro.2003.11.008]
- 22 **Fernandes MS**, Carneiro F, Oliveira C, Seruca R. Colorectal cancer and RASSF family--a special emphasis on RASSF1A. *Int J Cancer* 2013; **132**: 251-258 [PMID: 22733432 DOI: 10.1002/ijc.27696]
- 23 **Donninger H**, Vos MD, Clark GJ. The RASSF1A tumor suppressor. *J Cell Sci* 2007; **120**: 3163-3172 [PMID: 17878233 DOI: 10.1242/jcs.010389]
- 24 **Ortiz-Vega S**, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP, Avruch J. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. *Oncogene* 2002; **21**: 1381-1390 [PMID: 11857081 DOI: 10.1038/sj.onc.1205192]
- 25 **Rizzo S**, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F, Russo A. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? *Cancer Treat Rev* 2010; **36** Suppl 3: S56-S61 [PMID: 21129611 DOI: 10.1016/S0305-7372(10)70021-9]
- 26 **Vakiani E**, Solit DB. KRAS and BRAF: drug targets and predictive biomarkers. *J Pathol* 2011; **223**: 219-229 [PMID: 21125676 DOI: 10.1002/path.2796]
- 27 **Yokota T**. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? *Anticancer Agents Med Chem* 2012; **12**: 163-171 [PMID: 22043994 DOI: 10.2174/187152012799014968]
- 28 **Di Nicolantonio F**, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. *J Clin Oncol* 2008; **26**: 5705-5712 [PMID: 19001320 DOI: 10.1200/JCO.2008.18.0786]
- 29 **Asghar U**, Hawkes E, Cunningham D. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. *Clin Colorectal Cancer* 2010; **9**: 274-281 [PMID: 21208841 DOI: 10.3816/CCC.2010.n.040]
- 30 **Joseph EW**, Pratilas CA, Poulidakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. *Proc Natl Acad Sci U S A* 2010; **107**: 14903-14908 [PMID: 20668238 DOI: 10.1073/pnas.1008990107]

P- Reviewer Meshikhes AW S- Editor Gou SX L- Editor A  
E- Editor Yan JL



**GENERAL INFORMATION**

*World Journal of Gastrointestinal Oncology* (*World J Gastrointest Oncol*, *WJGO*, online ISSN 1948-5204, DOI: 10.4251) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

**Aim and scope**

*WJGO* covers topics concerning carcinogenesis, tumorigenesis, metastasis, diagnosis, prevention, prognosis, clinical manifestations, nutritional support, molecular mechanisms, and therapy of benign and malignant tumors of the digestive tract. The current columns of *WJGO* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography. Priority publication will be given to articles concerning diagnosis and treatment of gastrointestinal oncology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJGO*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

*WJGO* is edited and published by Baishideng Publishing Group (BPG). BPG has a strong professional editorial team composed of science editors, language editors and electronic editors. BPG currently publishes 42 OA clinical medical journals, including 41 in English, has a total of 15 471 editorial board members or peer reviewers, and is a world first-class publisher.

**Columns**

The columns in the issues of *WJGO* will include: (1) Editorial: The editorial board members are invited to make comments on an important topic in their field in terms of its current research status and future directions to lead the development of this discipline; (2) Frontier: The editorial board members are invited to select a highly cited cutting-edge original paper of his/her own to summarize major findings, the problems that have been resolved and remain to be resolved, and future research directions to help readers understand his/her important academic point of view and future research directions in the field; (3) Diagnostic Advances: The editorial board members are invited to write high-quality diagnostic advances in their field to improve the diagnostic skills of readers. The topic covers general clinical diagnosis, differential diagnosis, pathological diagnosis, laboratory diagnosis, imaging diagnosis, endoscopic diagnosis, biotechnological diagnosis, functional diagnosis, and physical diagnosis; (4) Therapeutics Advances: The editorial board members are invited to write high-quality therapeutic advances in their field to help improve the therapeutic skills of readers. The topic covers medication therapy, psychotherapy, physical therapy, replacement therapy, interventional therapy, minimally invasive therapy, endoscopic therapy, transplantation therapy, and surgical therapy; (5) Field of Vision: The editorial board members are invited to write commentaries on classic articles, hot topic articles, or latest articles to keep readers at the fore-

front of research and increase their levels of clinical research. Classic articles refer to papers that are included in Web of Knowledge and have received a large number of citations (ranking in the top 1%) after being published for more than years, reflecting the quality and impact of papers. Hot topic articles refer to papers that are included in Web of Knowledge and have received a large number of citations after being published for no more than 2 years, reflecting cutting-edge trends in scientific research. Latest articles refer to the latest published high-quality papers that are included in PubMed, reflecting the latest research trends. These commentary articles should focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions. Basic information about the article to be commented (including authors, article title, journal name, year, volume, and inclusive page numbers); (6) Minireviews: The editorial board members are invited to write short reviews on recent advances and trends in research of molecular biology, genomics, and related cutting-edge technologies to provide readers with the latest knowledge and help improve their diagnostic and therapeutic skills; (7) Review: To make a systematic review to focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions; (8) Topic Highlight: The editorial board members are invited to write a series of articles (7-10 articles) to comment and discuss a hot topic to help improve the diagnostic and therapeutic skills of readers; (9) Medical Ethics: The editorial board members are invited to write articles about medical ethics to increase readers' knowledge of medical ethics. The topic covers international ethics guidelines, animal studies, clinical trials, organ transplantation, *etc.*; (10) Clinical Case Conference or Clinicopathological Conference: The editorial board members are invited to contribute high-quality clinical case conference; (11) Original Articles: To report innovative and original findings in gastrointestinal oncology; (12) Brief Articles: To briefly report the novel and innovative findings in gastrointestinal oncology; (13) Meta-Analysis: Covers the systematic review, mixed-treatment comparison, meta-regression, and overview of reviews, in order to summarize a given quantitative effect, *e.g.*, the clinical effectiveness and safety of clinical treatments by combining data from two or more randomized controlled trials, thereby providing more precise and externally valid estimates than those which would stem from each individual dataset if analyzed separately from the others; (14) Case Report: To report a rare or typical case; (15) Letters to the Editor: To discuss and make reply to the contributions published in *WJGO*, or to introduce and comment on a controversial issue of general interest; (16) Book Reviews: To introduce and comment on quality monographs of gastrointestinal oncology; and (17) Autobiography: The editorial board members are invited to write their autobiography to provide readers with stories of success or failure in their scientific research career. The topic covers their basic personal information and information about when they started doing research work, where and how they did research work, what they have achieved, and their lessons from success or failure.

**Name of journal**

*World Journal of Gastrointestinal Oncology*

**ISSN**

ISSN 1948-5204 (online)

## Instructions to authors

### Launch date

October 15, 2009

### Frequency

Monthly

### Editorial-in-Chief

**Wasaburo Koizumi, MD, PhD, Professor, Chairman**, Department of Gastroenterology, Gastrointestinal Oncology, School of Medicine, Kitasato University, 2-1-1 Asamizodai Minamiku Sagamihara Kanagawa 252-0380, Japan

**Hsin-Chen Lee, PhD, Professor**, Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan

**Dimitrios H Roukos, MD, PhD, Professor**, Personalized Cancer Genomic Medicine, Human Cancer Biobank Center, Ioannina University, Metabatiko Kitirio Panepistimiou Ioanninon, Office 229, Ioannina, TK 45110, Greece

### Editorial Office

Jin-Lei Wang, Director

Xiu-Xia Song, Vice Director

*World Journal of Gastrointestinal Oncology*

Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China

Telephone: +86-10-59080039

Fax: +86-10-85381893

E-mail: [wjgo@wjgnet.com](mailto:wjgo@wjgnet.com)

<http://www.wjgnet.com>

### Publisher

Baishideng Publishing Group Co., Limited

Flat C, 23/F, Lucky Plaza, 315-321 Lockhart Road,

Wanchai, Hong Kong, China

Telephone: +852-65557188

Fax: +852-31779906

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

### Production center

Beijing Baishideng BioMed Scientific Co., Limited

Room 903, Building D, Ocean International Center,

No. 62 Dongsihuan Zhonglu, Chaoyang District,

Beijing 100025, China

Telephone: +86-10-85381892

Fax: +86-10-85381893

### Representative office

USA Office

8226 Regency Drive,

Pleasanton, CA 94588-3144, United States

Telephone: +1-925-2238242

Fax: +1-925-2238243

### Instructions to authors

Full instructions are available online at [http://www.wjgnet.com/1948-5204/g\\_info\\_20100312180518.htm](http://www.wjgnet.com/1948-5204/g_info_20100312180518.htm).

### Indexed and Abstracted in

PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

## SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

### Biostatistical editing

Statistical review is performed after peer review. We invite an ex-

pert in Biomedical Statistics to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Ridit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

### Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJGO* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: [http://www.icmje.org/ethical\\_4conflicts.html](http://www.icmje.org/ethical_4conflicts.html).

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

### Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

### Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

## SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book

Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

#### Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/esps/>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS ([http://www.wjgnet.com/1948-5204/g\\_info\\_20100312180518.htm](http://www.wjgnet.com/1948-5204/g_info_20100312180518.htm)) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to [wjgo@wjgnet.com](mailto:wjgo@wjgnet.com), or by telephone: +86-10-85381891. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

## MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

#### Title page

**Title:** Title should be less than 12 words.

**Running title:** A short running title of less than 6 words should be provided.

**Authorship:** Authorship credit should be in accordance with the standard proposed by International Committee of Medical Journal Editors, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

**Institution:** Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

**Author contributions:** The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

**Supportive foundations:** The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

**Correspondence to:** Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. [montgomery.bissell@ucsf.edu](mailto:montgomery.bissell@ucsf.edu)

**Telephone and fax:** Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381891 Fax: +86-10-85381893

**Peer reviewers:** All articles received are subject to peer review. Normally, three experts are invited for each article. Decision on acceptance is made only when at least two experts recommend publication of an article. All peer-reviewers are acknowledged on Express Submission and Peer-review System website.

#### Abstract

There are unstructured abstracts (no less than 200 words) and structured abstracts. The specific requirements for structured abstracts are as follows:

An informative, structured abstract should accompany each manuscript. Abstracts of original contributions should be structured into the following sections: AIM (no more than 20 words; Only the purpose of the study should be included. Please write the Aim in the form of "To investigate/study/..."), METHODS (no less than 140 words for Original Articles; and no less than 80 words for Brief Articles), RESULTS (no less than 150 words for Original Articles and no less than 120 words for Brief Articles; You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g.  $6.92 \pm 3.86$  vs  $3.61 \pm 1.67$ ,  $P < 0.001$ ), and CONCLUSION (no more than 26 words).

#### Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

#### Core tip

Please write a summary of less than 100 words to outline the most innovative and important arguments and core contents in your paper to attract readers.

#### Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: [http://www.wjgnet.com/1948-5204/g\\_info\\_list.htm](http://www.wjgnet.com/1948-5204/g_info_list.htm).

#### Illustrations

Figures should be numbered as 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part

## Instructions to authors

should be added into the text where the figures are applicable. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...*etc.* It is our principle to publish high resolution-figures for the E-versions.

### Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

### Notes in tables and illustrations

Data that are not statistically significant should not be noted. <sup>a</sup>*P* < 0.05, <sup>b</sup>*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, <sup>c</sup>*P* < 0.05 and <sup>d</sup>*P* < 0.01 are used. A third series of *P* values can be expressed as <sup>e</sup>*P* < 0.05 and <sup>f</sup>*P* < 0.01. Other notes in tables or under illustrations should be expressed as <sup>1</sup>F, <sup>2</sup>F, <sup>3</sup>F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, *etc.*, in a certain sequence.

### Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

## REFERENCES

### Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability<sup>[1,2]</sup>". If references are cited directly in the text, they should be put together within the text, for example, "From references<sup>[19,22-24]</sup>, we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

### PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

### Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

### Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial let-

ter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

### Format

#### Journals

*English journal article (list all authors and include the PMID where applicable)*

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

*Chinese journal article (list all authors and include the PMID where applicable)*

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarrhoea. *Shijie Huaren Xiaobua Zazhi* 1999; **7**: 285-287

*In press*

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

*Organization as author*

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 DOI:10.1161/01.HYP.0000035706.28494.09]

*Both personal authors and an organization as author*

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

*No author given*

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

*Volume with supplement*

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.s]

*Issue with no volume*

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; **(401)**: 230-238 [PMID: 12151900 DOI:10.1097/0000-3086-200208000-00026]

*No volume or issue*

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

#### Books

*Personal author(s)*

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

*Chapter in a book (list all authors)*

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

*Author(s) and editor(s)*

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiecezorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

*Conference proceedings*

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

*Conference paper*

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computa-

tional effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

#### Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

#### Patent (list all authors)

- 16 Pagedas AC, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

#### Statistical data

Write as mean  $\pm$  SD or mean  $\pm$  SE.

#### Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as  $\chi^2$  (in Greek), related coefficient as *r* (in italics), degree of freedom as  $\nu$  (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

#### Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h, blood glucose concentration, *c* (glucose)  $6.4 \pm 2.1$  mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 24.5  $\mu$ g/L; CO<sub>2</sub> volume fraction, 50 mL/L CO<sub>2</sub>, not 5% CO<sub>2</sub>; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: [http://www.wjgnet.com/1948-5204/g\\_info\\_20100312183048.htm](http://www.wjgnet.com/1948-5204/g_info_20100312183048.htm).

#### Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

#### Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kbo I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

#### Examples for paper writing

All types of articles' writing style and requirement will be found in the

link: <http://www.wjgnet.com/esps/NavigationInfo.aspx?id=15>

## SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED

Authors must revise their manuscript carefully according to the revision policies of Baishideng Publishing Group Co., Limited. The revised version, along with the signed copyright transfer agreement, responses to the reviewers, and English language Grade B certificate (for non-native speakers of English), should be submitted to the online system via the link contained in the e-mail sent by the editor. If you have any questions about the revision, please send e-mail to [esps@wjgnet.com](mailto:esps@wjgnet.com).

#### Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A.

#### Copyright assignment form

Please download a Copyright assignment form from [http://www.wjgnet.com/1948-5204/g\\_info\\_20100312182928.htm](http://www.wjgnet.com/1948-5204/g_info_20100312182928.htm).

#### Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: [http://www.wjgnet.com/1948-5204/g\\_info\\_20100312182841.htm](http://www.wjgnet.com/1948-5204/g_info_20100312182841.htm).

#### Proof of financial support

For papers supported by a foundation, authors should provide a copy of the approval document and serial number of the foundation.

#### Links to documents related to the manuscript

WJGO will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

#### Publication fee

WJGO is an international, peer-reviewed, OA online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium and format, provided the original work is properly cited. The use is non-commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. Publication fee: 600 USD per article. All invited articles are published free of charge.



百世登

**Baishideng**®

Published by **Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza, 315-321 Lockhart Road,

Wan Chai, Hong Kong, China

Fax: +852-65557188

Telephone: +852-31779906

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

